COURTNEY M. PRICE VICE PRESIDENT CHEMSTAR



MAR 2 6 2003

March 24, 2003

Via E-Mail and Overnight Courier

Dr. C. W. Jameson National Toxicology Program Report on Carcinogens MD EC-14 P.O. Box 12233 Research Triangle Park, NC 27709

> Re: National Toxicology Program (NTP), Call for Public Comments on 10 Nominations; Proposed for Listing in the *Report on Carcinogens*, Eleventh Edition; Federal Register, January 22, 2003 (Vol. 68, No. 14)

Dear Dr. Jameson:

The Naphthalene Panel of the American Chemistry Council submits these comments to NTP regarding the nomination of naphthalene for listing in the 11^{th} Report on Carcinogens (RoC) in response to the January 22, 2003, Federal Register notice. In response to previous Federal Register notices,¹ the Naphthalene Panel has submitted comments regarding naphthalene on the proposed nomination (comments dated September 24, 2001), the Draft Background Document (comments dated October 2, 2002), and the "Working Group for the Report on Carcinogens – RG-2 Naphthalene Review" review (comments dated November 4, 2002). The Naphthalene Panel also made an oral presentation in the brief time period allowed at the Board of Scientific Counselors (BSC) RoC Subcommittee (Subcommittee) meeting on November 19, 2002.

As part of the RoC process, NTP has elicited recommendations on the listing of naphthalene from NTP Staff (the "RG-1" working group), from NTP's Executive Committee (the "RG-2" working group) and from the BSC RoC Subcommittee. Unfortuneately, the RG-1 review occurred before publication of the *Draft Background Document*, the RG-2 review occurred after publication of the background document but before the date for receipt of public comments, and the BSC RoC Subcommittee based its decision apparently in large measure on

⁶⁶ Fed. Reg. 38430 (July 24, 2001); 67 Fed. Reg. 14957 (Mar. 28, 2002); 67 Fed. Reg. 36621 (May 24, 2002); 67 Fed. Reg. 59301 (Sep. 20, 2002).

Responsible Care®

information newly introduced at the Subcommittee meeting and not made available as of this date by NTP either on its website or in a revised background document or even in minutes of the meeting. This simple recitation of the calendar of the nomination, review, and now proposed listing of naphthalene makes evident that there has been no sincere effort to engage public stakeholders in the process, and no effort to ensure that "[NTP's] three scientific review committees are basing their decisions on the same basic material augmented by the additional public comments obtained during the review process."² Indeed, members of the public who were not physically present at the Subcommittee meeting are not even aware that a substantial part of the apparent basis for the Subcommittee meeting with either Subcommittee members or the public, and has not been made <u>publicly</u> available to those who may be interested in submitting comments in response to the January 22, 2003 Federal Register notice regarding nomination of naphthalene as *Proposed for Listing in the Report on Carcinogens, Eleventh Edition*.

Despite the Naphthalene Panel's continuing disappointment over past events, *viz* the mischaracterization of the science and the growing list of deficiencies in the process that has been followed to date in the nomination and review of the proposed listing of naphthalene, the Naphthalene Panel remains ever hopeful that, at long last, NTP will adhere to its self-described "transparent" process that is "open and fair, clear to all interested parties"³ and will consider these comments and attachments as well as those submitted previously. The Naphthalene Panel believes that NTP has no option but to start the review of naphthalene over if the collective record – including the transcript of the Subcommittee meeting - on the proposed listing of naphthalene by NTP is given serious consideration.

SUMMARY

The Naphthalene Panel urges that naphthalene not be listed in the *RoC*, *Eleventh Edition* for the following reasons:

- 1. Naphthalene does not meet the criteria to be listed as *Reasonably* Anticipated to be a Human Carcinogen:
 - 1.1. There is no credible evidence from studies in humans that naphthalene is a human carcinogen;
 - 1.2. The animal data are insufficient to conclude that naphthalene is associated with an increased incidence of malignant and/or benign tumors in multiple species or at multiple tissue sites;
 - 1.3. The animal data are insufficient to conclude that naphthalene is associated with an increased incidence of

² Letter from Dr. K. Olden, Director of NTP, to Ms. C. Price, Vice-President, CHEMSTAR of the American Chemistry Council dated March 11, 2003.

³ Ibid.

malignant and/or benign tumors by multiple routes of exposure;

- 1.4. The animal data are insufficient to conclude that naphthalene is associated with an increased incidence of malignant and/or benign tumors to an unusual degree with regard to incidence, site or type of tumor, or age at onset;
- 1.5. Naphthalene does NOT belong to a well defined, structurally-related class of substances whose members are listed in a previous *RoC* as either a known to be human carcinogen or reasonably anticipated to be human carcinogen;
- 1.6. There is NO convincing relevant information that naphthalene acts through mechanisms indicating it would likely cause cancer in humans; and
- 1.7. While there is evidence of carcinogenicity in one species of laboratory animals, there are compelling data indicating that napthalene acts through mechanisms which do not operate in humans and therefore, and on those grounds, cannot reasonably be anticipated to cause cancer in humans.
- 2. Should naphthalene be listed in the RoC, it would be the first substance to be listed based on "clear evidence" in one species of experimental animal, "some evidence" in one sex of a second species, and that is not genotoxic.
- 3. The process followed by NTP in nominating, reviewing, and potentially listing naphthalene in the *RoC*, *Eleventh Edition* has not been "open and fair, clear to all interested parties, and maintain[ing] the scientific rigor necessary for decisions regarding the review of agents for inclusion in the *RoC*."⁴

⁴ Ibid.

1. NAPHTHALENE DOES NOT MEET THE CRITERIA TO BE LISTED AS <u>REASONABLY ANTICIPATED TO BE A HUMAN CARCINOGEN</u>

1.1 There is no credible evidence from studies in humans that naphthalene is a human carcinogen

As concluded in the *Draft Background Document*⁵ and in the presentation of that document at the RoC Subcommittee meeting,⁶ the available human data are insufficient for evaluation of the carcinogenicity of naphthalene to humans. In addition, the review summary reports for both RG-1 and RG-2 each concluded that the very limited human data are insufficient for the evaluation of the carcinogenicity of naphthalene. Further, none of the RoC Subcommittee members appeared to have disagreed with the conclusions in the *Draft Background Document* concerning the insufficiency of the human data and one member, apparently reflecting the consensus view of the Subcommittee stated that the "human evidence isn't helpful, so we are going to be considering the animal evidence predominantly in our discussions."⁷

Nevertheless, the *Draft Background Document* is a document disseminated by NTP that should be accurate and should have provided a detailed explanation of the inadequacies of the two relatively old case studies described -- one an East German study dating from the 1970s and the other African case reports involving the oral intake of naphthalene containing compounds for medicinal purposes. This is particularly the case given that other recent NTP publications about naphthalene (*e.g.*, NTP 1992, 2000) have cited the East German reports of health effects observed in tar distillation workers, and used misleading summaries of these reports as part of the rationale for conducting assays in rodents. For the record the Naphthalene Panel wishes to point out some of the deficiencies of the German study.

NTP has, in its publications about naphthalene, used information contained in the East German reports (Wolf, 1976, 1978) to introduce a calculation that the data indicate a "greater than 4000-fold" increase in the incidence of the laryngeal cancers (NTP, 2000). This "4000-fold" figure appears to result from the ratio of 4/15 (incidence in naphthalene workers) to 6.3/100,000 (incidence in general male population in 1970). The increase in incidence actually presented in Wolf (1978) was a factor of 62. In evaluating the East German reports, the NTP *Draft Background Document* should have expressly stated that, although Wolf (1978) suggested that tar fumes in combination with heat may be causative factors, all four workers who developed laryngeal cancer were smokers, and the 15 workers in the study all were likely to have been exposed to many confounding factors in the workplace described by Wolf. The published statement by NTP (NTP, 2000, page 20) that the Wolf data indicate a "4000-fold" increase in

⁵ Draft Background Document at 21.

 $^{^{6}}$ Transcript (11/19/02) at 61.

⁷ Transcript (11/19/02) at 94.

tumor incidence is an example of an inaccuracy that should be corrected in the *Draft Background Document*.⁸

NTP (2000) also refers to a publication by Kup (1978) as though it contains additional information about workers exposed to naphthalene in East Germany. The Kup publication, however, seems to be a lecture or presentation, apparently before a group of medical scientists or physicians. Kup's report is far from comprehensive and the four cancer cases are not the sole topic of his lecture. They are just mentioned without reference to any cohort, but are clearly the cases discussed in detail by Wolf (1976, 1978). The *Draft Background Document* should include accurate discussions of the Wolf (1976, 1978) and Kup (1978) publications to correct misimpressions resulting from inaccurate discussions in previous NTP publications about naphthalene, such as TR 500 (NTP, 2000) and the suggestion that multiple human evaluations were performed.

The EU Risk Assessment Report concludes the following about the East German

studies:

Two brief reports are available of four cases of laryngeal cancer which occurred in workers engaged in the purification of naphthalene (Wolf, 1976; 1978). It is difficult to define from the reports whether the author identified these four cases independently or whether they were brought to his attention by an external source. However, it is clear from the reports that all the cases were smokers and were exposed to other substances including coal tar volatiles. Overall, no conclusion can be drawn from these reports regarding the role, if any, of naphthalene in the production of these cancers.⁹

The German BAuA (1998) notes the confounding factors in the East German cases and also notes that the cases referred to by Ajao *et al.* (1988) involved oral intake of "a concoction containing naphthalene." As is often the case with case reports, little information is available about the nature of possible confounding influences in the African reports.

EPA's Integrated Risk Information System (IRIS) database for naphthalene, last updated in September 1998, concludes with respect to human carcinogenicity data:

Available data are inadequate to establish a causal association between exposure to naphthalene and cancer in humans. Adequately scaled epidemiological studies designed to examine a possible association between naphthalene exposure and cancer were not located. Overall, no data are available to evaluate the carcinogenic potential in exposed human populations.

⁸ Translations of Wolf's reports were previously submitted to NTP by the Panel in its comments on the Draft Background Document.

⁹ EU (2002) at Section 4.1.2.8.2

1.2. The animal data are insufficient to conclude that naphthalene is associated with an increased incidence of malignant and/or benign tumors in multiple species or at multiple tissue sites

Mouse Study (NTP, 1992)

The NTP Technical Report for the mouse bioassay on naphthalene (NTP, 1992) found only that there was "some evidence of carcinogenic activity" of naphthalene in female $B6C3F_1$ mice, based on increased incidences of pulmonary alveolar/bronchiolar adenomas in the high dose group.¹⁰ The Technical Report did not make a finding of "clear evidence of carcinogenicity" in the test animals. An NTP study that finds that only "some evidence" of carcinogenicity, as opposed to "clear evidence," should be deemed insufficient in weight to warrant consideration under the NTP "reasonably anticipated to be a human carcinogen" standard.

Further, the statements in the current IRIS database on naphthalene (EPA, 1998) support that the NTP mouse study provides insufficient evidence of the carcinogenicity of naphthalene in mice. Addressing the NTP mouse study, it states: "An inhalation unit risk estimate for naphthalene was not derived because of the weakness of the evidence (observations of predominant benign respiratory tumors in mice at high dose only) that naphthalene may be carcinogenic in humans."¹¹ Indeed, only a single alveolar/bronchiolar carcinoma appeared among the 135 high dose female mice. No carcinomas were found in male mice. The NTP criteria regarding an increased incidence of malignant and/or combination of malignant and benign tumors clearly are not intended to pertain to an increased incidence of tumors that are so predominantly benign as in the case of the NTP mouse study.

The NTP mouse study (NTP, 1998) should not be considered by NTP for purposes of listing for the additional reason that "the pattern of toxicological evidence indicates that the mouse is more susceptible to the pulmonary toxicity of naphthalene than other species, and therefore the observed pulmonary adenomas seen in mice at [the high dose in the NTP study] are not considered to be of relevance to human health."¹²

Rat Study (NTP, 2000)

The Technical Report on the NTP rat bioassay on naphthalene (NTP, 2000) states that the incidences of neuroblastomas of the olfactory epithelium occurred with positive trends in male and female rats and that the incidence in the high dose females was statistically significant compared to controls. The Technical Report also reports a statistically significant increase in adenomas of the respiratory epithelium. J. Harkema's report, which is appended to the Naphthalene Panel's comments on the *Draft Background Document*, characterizes some of the rat respiratory epithelial tissue neoplasms as carcinomas whereas NTP's report (NTP, 2000) used

¹⁰ NTP (1992) at 36.

¹¹ EPA (1998) at Section II.C.

¹² EU (2002) at Section 4.1.2.8.3.

the terminology "adenomas" for all such tumors in the male rats and an increase in that tumor that was not statistically significant in the mid and high dose female rats.¹³ While these results indicate an increase in tumors in two different types of nasal tissue, the tumors all occurred in the nasal cavity. Therefore, it is clear that there was not an increase in malignant and/or a combination of malignant and benign tumors in multiple tissue sites because the nasal cavity is a single tissue site.

1.3 The animal data are insufficient to conclude that naphthalene is associated with an increased incidence of malignant and/or benign tumors by multiple routes of exposure

The route of administration in both the NTP rat study (NTP, 2000) and the NTP mouse study (NTP, 1992) was inhalation only and at high exposure concentration as compared to those to which humans would be exposed. Accordingly, by definition there is insufficient evidence from studies on naphthalene to conclude that there is an increased incidence of malignant and/or a combination of malignant and benign tumors by multiple routes of exposure.

1.4 The animal data are insufficient to conclude that naphthalene is associated with an increased incidence of malignant and/or benign tumors to an unusual degree with regard to incidence, site or type of tumor, or age at onset

The only malignant tumor increased in the NTP rat study (NTP, 2000) that possibly could be considered as induced to an unusual degree are the neuroblastomas seen in the nasal olfactory epithelium. The NTP report for that study notes that neuroblastomas of the nasal olfactory epithelium are rare neoplasms in rodents and humans. In addition, the report states that this tumor was not observed in the concurrent controls nor in NTP historical control databases. Even though these are rare tumors, several factors must be considered, before implicating the tumors as unusual under the NTP criteria for RoC listing. First, the historical control database for rats fed the NTP-2000 diet used in the NTP naphthalene bioassay is relatively small.¹⁴ Second, the EU Risk Assessment (EU, 2002) stated that the weight-of-the-evidence indicates that naphthalene is non-genotoxic (see discussion below as well as Schreiner, 2003), the tumors develop only at the sites where non-neoplastic inflammatory changes (atrophy, hyperplasia, and metaplasia) occur and thus concluded that the development of the nasal tumors is an apparent consequence of chronic tissue injury, for which an identifiable threshold of effect will exist.¹⁵ Tumors induced by such a common and non-specific mechanism of action should not be considered unusual, particularly when they occur at a site, as in the case of the nasal airway of the rat, where exposure to any irritating agent would be expected to cause inflammatory changes.

¹³ NTP (2002) at 36.

¹⁴ NTP (2000) at 28-29, 38 (Table 6, note "c").

¹⁵ EU (2002) at Section 4.1.2.8.3.

Third, neuroblastomas of the nasal olfactory epithelium have been induced by oral, inhalation, or peritoneal exposure to several structurally unrelated chemicals, and in several of these studies, the induction of the tumors occurred in conjunction with olfactory epithelial non-neoplastic lesions, as in the bioassay on naphthalene.¹⁶

It also is noted that anatomical, physiological, and metabolic differences between the rat and humans raise substantial questions as to the relevance of the rat nasal tumors to humans. This is discussed in detail in Section 1.7, below, and is another reason that the rat tumors cannot be a basis for listing naphthalene in the *RoC*.

1.5 Naphthalene does NOT belong to a well defined, structurally-related class of substances whose members are listed in a previous *RoC* as either a known to be human carcinogen or reasonably anticipated to be human carcinogen.

No scientifically sound inferences about the carcinogenicity or gentoxicity of naphthalene can be made by an overly broad comparison of naphthalene's structure to polyaromatics hydrocarbons (PAHs). Biologically active PAHs share a common mechanism for genotoxicity and carcinogenicity based on their structure, which allows for metabolic conversion via the CYP1A1 enzyme to an active dihydrodiol-epoxide. Unlike the PAHs, the metabolism of naphthalene is under the control of the CYP2F enzyme family, not the CYP1A family, and does not lead to the formation of a dihydrodiolepoxide but instead form naphthalene-1,2-oxide.

While some chemists would agree that naphthalene can be technically classified as a PAH for purposes of definitional nomenclature, the importance of PAHs as a group is associated with their biological activity. Naphthalene is both biologically and structurally distinct from biologically active genotoxic and carcinogenic PAHs. Biologically active PAH's share a common mechanism for genotoxicity and carcinogenicity based on their structure. Although planar fused ring compounds (PAHs) vary considerably in their biological activity, genotoxic PAHs are indirect-acting or promutagens, meaning that genotoxicity is expressed following metabolic conversion of the PAH to an active species. The mechanism by which PAHs are thought to induce tumor formation is via interaction with genetic material within target cells, either frank mutagenicity or interference with normal genetic biology as a result of PAHadduct formation with nuclear material. Accordingly, it is generally observed that the genotoxic potency of PAHs closely parallels the carcinogenic potency. However, this relationship is based on experience with PAHs having greater than two fused rings. Naphthalene does not have greater than two fused rings and results of numerous studies suggests that it is not mutagenic (see Section 1.6), i.e., naphthalene does not appear to interact with DNA. Moreover, photomutagenicity, or the property of enhancing the mutagenicity of non-ionizing radiation, has been reported for carcinogenic PAHs (with greater than two fused rings) and can account for the observation of a lack of mutagenicity in highly carcinogenic neutral PAH mixtures (Selby,

¹⁶ NTP (2000) at 42.

1986). There are no reports of the photomutagenicity of naphthalene. The presence of antimutagens in carcinogenic PAH mixtures has also been suggested to account for the difference in activity observed between isolated components of a mixture and the intact mixture (Slaga, 1979). There is no information suggesting that naphthalene can exhibit activity of the type associated with PAHs having greater than two fused rings.

There is information to suggest that the active structure of some PAHs is a reactive arene oxide, in older literature termed the bay region diol-epoxide. A bay region diol-epoxide is formed in a PAH when <u>three rings</u> are fused in a way to create a pocket, the "bay". Bay region diol epoxides are formed enzymatically in humans by a P450 enzyme, CYP1A1. The ability and ease of a PAH to form a bay region diol epoxide can be calculated. This has lead to a great deal of work in structure-activity-relationship (SAR) assessment of the potential for carcinogenicity of PAH compounds - but only PAH compounds with three or more fused rings.

In addition to the recognition of the importance of the bay region to genotoxicity and carcinogenicity of PAHs, it has been observed that the addition of a substituent group, almost always a methyl group, in or opposite to the bay region containing the epoxide impacts on PAH biologic activity. There are numerous examples of the alkylation of the PAH (with a methyl group) both enhancing and eliminating PAH tumorigenicity and mutagenicity (Saas, 1996; Slaga, 1979, Thakker, 1979).

The large and long-standing body of information relating to carcinogenic characteristics of PAHs, whether it be induction or suppression of genotoxic/carcinogenic activity, has not been associated with naphthalene. To date, a unified SAR theory does not exist to account for the observations of PAH carcinogenicity, particularly for PAHs that are substituted beyond the methyl state (nitroaromatics and branched chain alkylated PAHs, for instance). Various illuminating bodies of work have evaluated the carcinogenic effect of methyl-, ethyl-, and propyl-substitutions on fused-ring PAHs such as chrysene. Methylation has been shown to transform inactive PAHs to active and to deactive carcinogenic PAHs. For example, methylchrysene is a more potent lung carcinogen than chrysene, but ethyl- and propyl-chrysene are less potent. Similarly, bay region methylation of dimethylbenzanthracene, a potent mutagen and carcinogen, completely blocks mutagenic and carcinogenic activity. However, none of these observations characteristic of PAH carcinogenicity have been found applicable to "PAHs" with less than three fused rings. In fact, no approach to PAH carcinogenic SAR, whether involving electron cloud density theories or methods of analysis involving statistics and artificial intelligence, includes naphthalene in the paradigm.

Accordingly, the statement by a member of the RoC Subcommittee that, because of napththalene's structure, "naphthalene belongs to an agent, substance, or mixture which belongs to a well-defined structurally-related class of substances...I would suggest that naphthalene is a two-ringed PAH, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity"¹⁷ does not comport with the body of toxicology knowledge assembled on the carcinogenic characteristics of PAH compounds.

¹⁷ Transcript (11/19/02) at 99-100.

> 1.6 There is NO convincing relevant information that naphthalene acts through mechanisms indicating it would likely cause cancer in humans

Presentations made by representatives of NTP and of the Naphthalene Panel at the RoC Subcommittee meeting on November 19, 2002 both included summaries of the well studied metabolism of naphthalene. A key point made by both presenters was the relationship of naphthalene metabolism to species-specific organ toxicity. The species- and tissue-specific toxicity has been attributed to difference in metabolism (Sweeney *et al.*, 1996; O'Brien *et al.*, 1985).

As shown in Figure 1, naphthalene is metabolized by cytochrome P450 isoenzymes to naphthalene-1,2-oxide (also referred to as naphthalene epoxide) and subsequently to 1,4,-naphthalediol and 1,2-naphthalenediol. The diols are oxidized, either enzymatically or non-enzymatically to 1,4-naphthoquinone and 1,2-naphthoquinone, respectively. In the mouse lung naphthalene metabolism favors the formation of the 1R2S-oxide while in the rat and hamster lung, metabolism predominantly goes through the 1S2R-oxide. The differences in tissue responses between rats and mice have been ascribed to stereoisomeric differences (Buckpitt *et al.*, 2002). The relationship of this differential metabolism and its potential relationship to the formation of lung tumors in mice and nasal olfactory tumors in rats have been described in previous documents submitted by the Naphthalene Panel'.

During the Subcommittee deliberations, a Subcommittee member opined that the metabolism of naphthalene should be looked at in a complex fashion rather than focusing on the stereochemistry of the epoxides and that only mechanistic pathways that are entirely believable and reasonable and should be considered seriously when the Subcommittee makes its final decision¹⁸. The alternative metabolism proposed by the Subcommittee member was that of the three ring (and greater) PAHs. Section 1.5 of these comments contains discussion of the differences between PAHs with three or more rings and naphthalene. The Naphthalene Panel takes issue with the characterization that the role of epoxides in tissue injury is not believable and reasonable. The literature over the past 20 years supports the role of naphthalene epoxide in tissue-specific toxicity (see recent review by Buckpitt *et al.*, 2002). An alternative pathway suggested by this Subcommittee member posits that the naphthoquinones and the reactive oxygen species that follow are an important mechanistic pathway that could, in part, explain the carcinogenicity of naphthalene. Extensive research on naphthalene metabolism does not support this.

The Naphthalene Panel agrees that it is important to evaluate appropriate mechanistic pathways in assessing risks associated with xenobiotics. Further, the Panel does agree that the literature demonstrates that low levels of naphthoquinones may be formed via metabolism of naphthalene. In its discussions, however, the RoC Subcommittee failed to give sufficient consideration to well established metabolic pathways and potential mechanisms of

¹⁸ Transcript (11/19/02) at 111.

tumorigenicity but rather focused solely on speculations that a minor metabolite should be considered relevant in contradiction to all published research on naphthalene metabolism.

Recently published studies evaluated the formation of hemoglobin and albumin adducts by naphthalene-1,2-oxide, 1,2-naphthoquinone and 1,4 naphthoquinone after naphthalene administration to F344 rats (Waidyantha *et al.*, 2002; Troester *et al.*, 2002). Results show that the levels of hemoglobin adducts formed with the epoxide greatly exceeds the levels of adducts from either of the quinones. In contrast, the amounts of naphthoquinone bound to albumin are very similar to the amounts of epoxide bound to albumin. In light of discussions by the RoC Subcommittee focused on the importance of naphthoquinone, the question is whether the levels of naphthoquinone produced during metabolism of naphthalene rise to levels of toxicological concern.

To support the relevance of naphthoquinones in the tumorigenic process data, a document was presented to the Subcommittee that apparently included published data from the literature thought to be germane to the naphthalene review. This document was prepared outside of the public comment period and not shared with the public before, at or after the meeting. Nonetheless, this document became the main focus of the Subcommittee's deliberations regarding naphthalene.

Following the meeting, the Naphthalene Panel was supplied four citations from the literature that apparently were included in the new document presented to the Subcommittee (Flowers-Geary *et al.*, 1996; McCoull *et al.*, 1999; Penning *et al.*, 1999; Yu *et al.*, 2002). None of these publications involves evaluation of naphthalene. Rather each addresses the synthesis, reactivity, binding, and mutagenicity of PAH o-quinones. These papers support a conclusion the PAH o-quinones and reactive oxygen species generated by o-quinone are mutagenic. The papers are silent about naphthalene.




Figure 1. Proposed pathways for Naphthalene metabolism (from ATSDR report, update 1995)

When evaluating naphthalene, it is important to consider results from studies with naphthalene *per se* in relationship to similar studies with metabolites. A RoC Subcommittee member stated that "the argument that naphthalene is not genotoxic is simply not true unless one decides to eliminate or not take into consideration the products of metabolism."¹⁹ The Naphthalene Panel does not concur with this statement for the following reasons:

- A. Testing of metabolites at high concentrations is not relevant to low levels of metabolites generated *in vivo*.
- B. The genotoxic potential of naphthalene *per se* has been extensively evaluated. Review of the published literature shows that there are 33 non-mammalian and mammalian cell *in vitro* assays giving negative results. Additionally, there are four *in vivo* assays that were negative. A number of the *in vitro* studies were conducted under conditions of metabolic activation and, of course, naphthalene would be metabolized in the *in vivo* studies. If naphthoquinone formation were significant, positive responses would have been expected. Clearly, this is not the case. For example, a RoC Subcommittee member cited positive findings for four Ames strains tested with naphthoquinone as providing strong evidence of potential mutagenicity for naphthalene.

The conditions (*i.e.*, metabolic activation or non-activation) were not stated. The literature contains ten Ames studies with naphthalene, covering 33 evaluations covering five tester strains (six assays with TA1535; eight assays with TA1537; eight assays with TA100; nine assays with TA98; and two assays with TA1538) under conditions of both metabolic activation and non-activation (Schreiner, 2003). These studies were negative and support a conclusion that the level metabolically produced naphthoquinone do not rise to the level of inducing genotoxicity.

It was also stated by the *RoC* Subcommittee member that positive results from a "modern" mutational frequency study with p53 needs to be taken with some seriousness as opposed to more traditional mutagenicity assays. It should be noted that these "modern" results were derived from an *in vitro* study with PAH o-quinones (Yu *et al.*, 2002) and the study authors concluded that no mutants were observed with PAH o-quinone alone. This study, although presented as supporting the genotoxicity of naphthoquinone, does not.

C. A *RoC* Subcommittee member stated "...you really can't apply weight of evidence across genotoxicity studies."²⁰ This statement was made to override the weight of evidence from naphthalene genotoxicity studies that

¹⁹ Transcript (11/19/02) at 108-109.

²⁰ Transcript (11/19/02) at 126.

> is overwhelmingly negative. It may be that this Subcommittee member is unaware of the mutagenicity risk assessment procedures published by EPA that are used in evaluating the carcinogenic potential of pesticides and industrial chemicals (Russell *et al.*, 1984; EPA, 1986). These procedures are a weight of evidence analysis of all genetic toxicity data and affirm the conclusion reached by various regulatory bodies, including IARC and NTP, that the weight of evidence from naphthalene genotoxicity studies is overwhelmingly negative (Schreiner, 2003).

It seems that the underlying mechanistic information presented by NTP in its *Draft Background Document* (NTP, 2002) and its oral presentation, and by the Naphthalene Panel in its comments and oral presentation at the RoC Subcommittee meeting was lost in the Subcommittee's debate over metabolism of (three ring) PAHs.

The Naphthalene Panel agrees that mechanistic pathways should have been considered seriously when the committee made its final determination.²¹ Inexplicably, as the transcript of the meeting shows, the RoC Subcommittee's evaluation of mechanistic considerations focused little attention on the nasal olfactory tumors, especially given that naphthalene is not genotoxic. Considerations such as mechanisms of tumor formation are well recognized components of the risk characterization process (Williams and Paustenbach, 2002) and are one of the factors to be considered under NTP's listing criteria.

1.7 While there is evidence of carcinogenicity in rats, there are are compelling data indicating that napthalene acts through mechanisms which do not operate in humans and would therefore not reasonably be anticipated to cause cancer in humans

NTP's listing criteria state that even where there is evidence of carcinogenicity in laboratory animals for a particular agent, where there are compelling data indicating that the agent acts through mechanisms which do not operate in humans, the agent would not reasonably be anticipated to cause cancer in humans and therefore would not be listed in the *RoC*.

There are compelling data indicating that naphthalene causes nasal tumors in rats by mechanisms that do not operate in humans. Anatomical, physiological, and metabolic differences between the rat and humans raise substantial questions as to the relevance of the rat nasal tumors to humans. Human nasal physiology is significantly different from that of rodents. A primary site of action for toxic effects in rats is the olfactory epithelium, which comprises a significant portion of the total nasal cavity. The rat is an obligatory nose breather and must rely on olfaction for survival. The olfactory mucosa in rats is a highly developed system of cellular structures that performs complicated integration of olfaction and air humidification. Approximately 50% of the total surface area of the posterior region of the rat nasal cavity is comprised of the olfactory epithelium (Gross *et al.*, 1982; Uriah and Maronpot, 1990). Inhaled

²¹ Transcript (11/19/02) at 111.

vapors need traverse only a few millimeters past the resistant respiratory epithelium to reach the sensitive olfactory tissue in rats.

By comparison, the total surface area for chemical exposure is much less in humans (by a factor of five) since human nasal turbinates are much less convoluted than in the rodent. The olfactory epithelium comprises only about 10% of the human nasal cavity and is confined to the posterior dorsal region of the nasal cavity (Frederick *et al.*, 1994). The ciliated respiratory epithelium is the major lining of the human nasal cavity. In humans, inhaled vapors must traverse several centimeters through the ciliated respiratory epithelium before reaching the olfactory epithelium. Through mucociliary actions, the respiratory epithelium provides a protective system for the olfactory epithelium and other respiratory tissues. As a result of these differences, the efficiency of extracting chemicals from air inhaled through the nose is much less in humans than in rodents, which rely heavily on their sense of smell to locate food. The resulting dose deposited to the human olfactory epithelium, in particular, from inspired air is far less than for rodents for any given naphthalene concentration in air.

As noted above, irritation occurred in the nasal olfactory and respiratory epithelium in the NTP rat study (as well as in the NTP mouse study). Also as explained, it is likely that irritation plays a central role in the induction of nasal tumors seen in the rat. This conclusion is supported by the fact that naphthalene is largely negative in genotoxicity studies. Moreover, both the Draft EU Risk Assessment,²² as well as the EU Scientific Committee on Occupational Exposure Limits,²³ concur that chronic cytotoxicity is the likely mechanism for the tumorigenic effects of naphthalene in the rat nasal cavity. Given the factors discussed above, it appears unlikely that such chronic cytotoxicity in olfactory epithelium would occur in humans under conditions of naphthalene use.

Differences in the rate of metabolism and the character of the metabolites of naphthalene in rats and humans also support the hypothesis that the NTP rat bioassay results are not relevant to humans. Of all mammalian species, the human has the greatest capacity for the detoxification of naphthalene epoxide, the initial metabolite of naphthalene. This epoxide is a reactive and short-lived intermediary metabolite, which is thought to be the proximate carcinogen in the rat causing the neuroblastoma. Humans metabolize naphthalene effects. As explained by Kitteringham, *et al.* (1996), "... both rodent species [(rat and mouse)] showed consistently low (epoxide hydrolase) activity which, coupled with the possibility of differences in substrate specificity, cautions against the choice of rodent species for toxicity testing of compounds for which epoxide intermediates are suspected metabolites" (Kitteringham et al., 1996).

²² Draft EU Risk Assessment, at Section 4.1.2.8.3.

 ²³ SCOEL (Scientific Committee on Occupational Exposure Limits) (2001).
 "Recommendation from Scientific Committee on Occupational Exposure Limits for Naphthalene." SCOEL/SUM/90 final, June, 2001.

In light of the foregoing anatomical, physiological, and metabolic considerations, there are substantial questions about the relevance of the rat nasal tumors to humans. These questions are of sufficient degree to preclude a finding that naphthalene is "reasonably anticipated to be a human carcinogen," under conditions of use. This conclusion is corroborated by the mechanistic information discussed in Section 1.6 above.

2. SHOULD NAPHTHALENE BE LISTED IN THE ROC, IT WOULD BE THE FIRST SUBSTANCE TO BE LISTED BASED ON "CLEAR EVIDENCE" IN ONE SPECIES OF EXPERIMENTAL ANIMAL, "SOME EVIDENCE" IN ONE SEX OF A SECOND SPECIES, AND THAT IS NOT GENOTOXIC²⁴.

The scientific findings summarized above do not suggest that naphthalene should be listed as "reasonably anticipated" to be a human carcinogen. As noted in Section 1.2 above, the basis for "some evidence" of carcinogenicity in female mice is one carcinoma in one of 135 female mice. This evidence is weak at best. Importantly, NTP should not use naphthalene or any other individual substance to affect a "change by precedent" in RoC listing evidence requirements. Any change to NTP's listing criteria should be submitted for review to RG-1 and RG-2 followed by a notice in the Federal Register that would allow all affected parties, including other agencies, the opportunity for review and comment.

3. THE PROCESS FOLLOWED BY NTP IN NOMINATING, REVIEWING AND POTENTIALLY LISTING NAPHTHALENE IN THE *ROC*, *ELEVENTH EDITION* FALLS FAR SHORT OF NTP'S COMMITMENT TO BEING "OPEN AND FAIR, CLEAR TO ALL INTERESTED PARTIES, AND MAINTAIN[ING] THE SCIENTIFIC RIGOR NECESSARY FOR DECISIONS REGARDING THE REVIEW OF AGENTS FOR INCLUSION IN THE *ROC*."

The Naphthalene Panel believes strongly that the events that transpired at the November 19, 2002, RoC Subcommittee meeting with respect to naphthalene were serious transgressions of scientific rigor and due process. These are described in detail in the Naphthalene Panel's letters of March 3, 2003 and November 27, 2002 to Dr. Kenneth Olden, Director NTP. Those letters and Dr. Olden's responses dated January 27, 2003 and March 11, 2003 are attached and should be considered part of the Naphthalene Panel's submitted comments.

In summary, the transgressions included an unexpected technical presentation focussed on information of no apparent utility to understanding naphthalene carcinogenicity delivered to the Subcommittee by the Chairman of the Subcommittee who subsequently voted on the disposition of naphthalene. The presentation allegedly included new information purporting to relate naphthalene to the carcinogenicity of PAHs that had neither been shared prior to the meeting with the Subcommittee, nor since made a part of the public record. At least some of the

²⁴ Transcript (11/19/02) at 98.

information provided (the four citations discussed in Section 1.6, above) concerned major metabolites of PAHs with three or more rings and did not address naphthalene. Moreover, this objectionable and inappropriate approach has continued to this day, with the apparent approval of NTP, as none of the materials presented are yet part of the public record. Indeed, none of this information was available for public comment before the Subcommittee meeting, after it, or at present. The information is only available through a request for the meeting transcript, included as an attachment to these comments.

A possibly even more glaring process error is the fact that the Draft Background Document on naphthalene remains in its orignal form, with its contents unchanged from its August 26, 2002, cover date. Neither the RG-1 findings nor the RG-2 findings are reflected in the Draft Background Document despite the requirements of NTP's own procedures that the Draft Background Document be so revised. Both on its web site and in correspondence from Dr. Olden, the Draft Background Document is described as the "document of record" for RoC decisions. Further, in Dr. Olden's letter of March 11, 2003, it is stated that NTP does "not alter the background document throughout the review period unless serious errors are detected in it. This assures that our three scientific review committees are basing their decisions on the same basic material augmented by additional public comment obtained during the review process" [italics added for emphasis]. The problem with this is it assumes the Draft Background Document is fundamentally correct when issued. Where, as here, the Draft Backround Document is fundamentally flawed and despite repeated requests to remedy these flaws, the document remains unchanged, presumably only because of the process reasons given in Dr. Olden's letters. This contributes to the appearance and perceptions that NTP's solicition for public comment is little more than a meaningless exercise in the form of transparency rather than the function; in going through the motions of stakeholder involvement rather than the actions.

More to the point, in this instance, NTP's actions betray a double standard. On the one hand, the naphthalene *Draft Background Document* remains unchanged despite voluminous evidence offered by the Naphthalene Panel that it is materially incorrect. On the other hand, when the Chairman of the RoC Subcommittee spoke at the November meeting, presented for the first time new data and his interpretation of this data to his colleagues on the Subcommittee, the public was expressly denied an opportunity to comment on these data. This denial continues to this day as none of the presentation, remarks, or other "new" information relating to PAHs with three or more rings presented at the RoC Subcommittee meeting are available for comment. The Chairman's exercise of executive perogitive was inappropriate last November, continues to be inappropriate, and is in sharp contrast with NTP's stated ideal that the three scientific review committees (two of which met before the end of the comment period on the *Draft Background Document*) based their decisions on the "same basic material augmented by additional public comment obtained during the review process." Clearly, this is not the case as the PAH information is unrelated to the "same basic material" embodied by the *Draft Background Document*.

Rather than repeat here in detail all the many procedural errors and due process transgressions the Naphthalene Panel already has brought to NTP's attention, the November 27,

2002 and March 3, 2003 letters are attached and incorporated by reference here. Additionally, and for purposes of clarity and to ensure the record is complete, Dr. Olden's January, 27, 2003 and March 11, 2003 responses to the Naphthalene Panel's letters also are attached, as is a copy of the transcript of the November 19, 2002 Subcommittee meeting.

Based on the objectivity, utility and integrity of the data used to to date by NTP throughout the review of naphthalene, if NTP does not withdraw the *Draft Background Document* and consider naphthalene anew, the Naphthalene Panel will be forced to consider an Information Quality Act Petition requesting a "Predissemination Review" of the proposed listing of naphthalene in the Eleventh RoC.

CONCLUSION

The Naphthalene Panel renews its request that NTP immediately withdraw the *RoC Draft Background Document* for naphthalene, for all the reasons noted above and in the Panel's prior submissions. Further, the Panel requests that NTP suspend all further action on napthalene until the *Draft Background Document* has been revised to reflect fully and accurately all available information and comments submitted on the recommendation to list napthalene. The Panel also renews its request that NTP nullify the vote on napthalene by the RoC Subcommittee and schedule napthalene for review at the next RoC Subcommittee meeting. Acceding to these minimal requests and giving the review of naphthalene a fresh start will go a long way towards correcting the procedural and due process infractions that have characterized the listing process thus far. If NTP declines to provide this reasonable relief, the Naphthalene Panel asks that NTP advise the Naphthalene Panel of its decision before forwarding a recommendation to list naphthalene to the Secretary, Department of Health and Human Services and allow the Naphthalene Panel to meet with NTP.

If you seek additional information, please call or e-mail Dr. Anne P. LeHuray at (703) 741-5630 or *anne_lehuray@americanchemistry.com*.

Sincerely yours,

Signature

Courtney M. Price Vice President, CHEMSTAR

Attachments

Mr. Tommy Thompson, Department of Health and Human Services (HHS)
 Dr. K. Olden, NTP
 Dr. Christopher Portier, NTP
 Dr. Dr Elias A. Zerhouni, Director, National Institutes of Health (NIH)

REFERENCES

- Ajao, O.G., Adunuga, M.O. and Ladipo, J.K. (1988). Colorectal carcinoma in patients under the age of 30 years: a review of 11 cases. J. R. Coll. Surg. Edinb. 33: 277-279.
- ASTDR (Agency for Toxic Substances and Disease Registry) 1995. Update toxicological profile for naphthalene. Final update. US Dept. of Health and Human Services, US Public Health Service, Atlanta, GA
- Barfknecht, T.R. 1985. Rat hepatocyte primary cultures/DNA repair test: Naphthalene. EPA Regis. No. 62766-1 (1991). Pharmakon Research International, Inc., Waverly, PA.
- Braga, R. S., et al., Identifying carcinogenic activity of methylated polycyclic aromatic hydrocarbons. 1999, Theochem. 464:1-3, 257-266.
- Buckpitt, A. *et al.* (1992). Relationship of cytochrome P450 activity to Clara cells Cytotoxicity: II. Comparison of stereoselectivity of naphthalene epoxidation in lung and nasal mucosa of mouse, hamster, rat and Rhesus monkey. *J. Pharmacol. Exp. Therap.*, 261, 364-372.
- Buckpitt, A., B. Boland, M. Isbell, D. Morin, M. Shultz, R. Baldwin, K. Chan, A. Karlsson, C. Lin, A. Taff, J. West, M. Fanucchi, L.Van Winkle, and C. Plopper (2002). Naphthalene induced respiratory tract toxicity: Metabolic mechanisms of toxicity. *Drug Metabolism Reviews*, in press.
- Buckpitt, A., Boland, B, Isbell, M., Morin, D., Shultz, M., Baldwin, R., Chan, K., Karlsson, A., Lin, C., Taff, A., West, J., Fanucchi, M., Van Winkle, L., and Plopper, C. (2002). Naphthalene induced respiratory tract toxicity: Metabolic mechanism of toxicity.
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin [BAuA; Federal Institute for Occupational Safety & Health] (1998). German Comments on the Classification of Naphthalene (CAS no.: 91-20-3). COM.ECB4/020/98.
- EPA (1986). Guidelines for Mutagenicity Risk Assessment, Federal Register, Vol. 51, No. 185, pages 34006-34012, September 24, 1986.
- EPA (1998). IRIS Substance File for Naphthalene, http://www.epa.gov/iris/subst/0436.htm.
- EPA (1999). 64 Fed. Reg. 46771 (Aug. 26, 1999).
- EPA (2002). Announcement of Preliminary Regulatory Determinations for Priority Contaminants on the Drinking Water Contaminant Candidate List. Federal Register: June 3, 2002 (Volume 67, Number 106).
- EU (2002). European Union Risk Assessment Report: Naphthalene, CAS Number 91-20-3, EINECS Number 202-049-5. Final Report, March 2002. United Kingdom Health and Safety Executive (UK HSE).
- Frederick, C.B., Morris, J.B., Kimbell, J.S., Morgan, K.T., Scherer, P.W. (1994). "Comparison of four biologically based dosimetry models for the deposition of rapidly metabolized vapors in the rodent nasal cavity." *Inh. Toxicol.* 6(suppl.):135-157.

- Flowers-Geary L, Bleczinski W, Harvey RG, Penning TM. Cytotoxicity and mutagenicity of polycyclic aromatic hydrocarbon o-quinones by dihydrodiol dehydrogenase. Chemico-Biological Interactions 99: 55-72 (1996).
- Gollahon, L.S., Iyer, P., Martin, J.E., and Irwin, T.R. 1990. Chromosomal damage to preimplantation embryos *in vitro* by naphthalene. *The Toxicologist* 10: 274 (abst. #1094).
- Gross, E.A., Swenberg, J.A., Fields, S., Pop, J.A. (1982). "Comparative morphometry of the nasal cavity in rats and mice." J. Anat. 135:83-88.
- Harper, B.L., Sadagopa Ramanujam, V.M., Gad-El-Karim, M.M., and Legator, M.S. (1984). The influence of simple aromatics on benzene clastogenicity. *Mutat. Res.* 128: 105-114.
- Kitteringham, N.R., Davis, C., Howard, N., Pirmohamed, M., Park, B.K., (1996). "Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene." J. Pharmacol. Exp. Ther. 278(3):1018-1-27.
- Kup, W. (1978). Work-related origin of cancer in the nose, mouth, throat, larynx. Akad. Wiss. 2: 20-25 [as cited in NTP, 2002].
- McCoull KD, Rindgen D, Blair IA, Penning, TM, Synthesis and characterization of polycyclic aromatic hydrocarbon o-quinone depurinating N7-guanine adducts. Chemical Research in Toxicology 12: 237-246 (1999).
- National Institute for Occupational Safety and Health (NIOSH) (1983): National Occupational Exposure Survey (NOES): Final Report. Contract Number 210-80-6057, Cincinnati, Ohio.
- NTP (1992). Toxicology and Carcinogenesis Studies of Naphthalene (CAS No. 91-20-3) in B6C3F₁ Mice (Inhalation Studies) (Apr. 1992), Technical Report No. 410 (NTP Mouse Bioassay).
- NTP (2000). Toxicology and Carcinogenesis Studies of Naphthalene (CAS No. 91-20-3) in F344/N Rats (Inhalation Studies) (Dec. 2000), Technical Report No. 500 (NTP Rat Bioassay).
- NTP (2001). Call for Public Comments on 16 Substances, Mixtures and Exposure Circumstances Proposed for Listing in the Report on Carcinogens, Eleventh Edition; 66 Fed. Reg. 38430 (July 24, 2001).
- NTP (2002). Draft Report on Carcinogens Background Document for Naphthalene. August 26, 2002.
- O'Brien, K.A., Smith, L.L., and Cohen, G.M. (1985). Differences in naphthalene-induced toxicity in the mouse and rat. Chem. Biol. Interact. 55:109-122.

- Penning TM, Burczynski ME, H C-F McCoull KD, Palackal NP, Tsuruda LS. Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones. Chemical Research in Toxicology 12(1): 1-15 (1999).
- Purchase, I.F.H., Longstaff, E., Ashby, J., Anderson, D., LeFevre, P.A., Westwood, F.R. (1978). An evaluation of 6 short-term tests for detecting organic chemical carcinogens. *Brit. J. Cancer* 37: 873-959.
- Research Toxicology Center (RTC) (1999). Naphthalene Unscheduled DNA synthesis (UDS) after *in vivo* treatment. Monitored by Rutgers VFT AG; sponsored by International Tar Assoc. Research Toxicology Center, Rome, Italy.
- Russell, L.B., Aaron, C.S., deSerres, F., Generoso, W.M., Kannan, K.L., Shelby, M., Springer, J. and Voytek, P. (1984) A report to the U.S. Environmental Protection Agency Gene-Tox Program: Evaluation of mutagenicity assays for purposes of genetic risk assessment. Mutation Research 134: 143-157.
- Saas. P. et al., Effects of methyl substitutions on benz(a)anthracene derivative-induced immunosuppression. 1996, J. of Toxicol and Environ Health 49, 371-387.
- Schreiner, C.A. (2003). Genetic Toxicity of Naphthalene: A Review. Journal of Toxicology and Environmental Health, Part B, 6:161-183.
- Selby, C. P., et al., Chemical basis of photomutagenicity in synthetic fuels and correlation with carcinogenicity. 1986. Mut Res 188:4, 287-299.
- Shultz, M. *et al.* (2001). Metabolic capabilities of CYP2F2 with various pulmonary toxicants and its relative abundance in mouse lung subcompartments. *J. Pharmacol. Exp. Therap.*, 296, 510-519.
- Slaga, T. J., et al., "Comparison of skin tumor initiating activities of dihydrodiols, diol- epoxides and methylated derivatives of various polycyclic aromatic hydrocarbons" in <u>Polynuclear</u> <u>Aromatic Hydrocarbons: Chemistry and Biological Effects: Fourth International</u> <u>Symposium</u>, 1979, Bjorseth and Dennis, eds., Battelle Press, Columbus, Ohio, pp. 753-769.
- Sorg, R.M. (1985). Micronucleus test (MNT) OECD: Naphthalene. EPA Regis No. 62766-1 (1991). Pharmakon Research International, Inc., Waverly, PA.
- Sweeney, L.M., Shuler, M.L., Quick, D.J., and Babish, J.G. (1996). A preliminary physiologically based pharmacokinetic model for naphthalene and naphthalene oxide in mice and rates. Ann. Biomed. Eng. 24:305-320.
- Thakker, D. R., "Comparative metabolism of polycyclic aromatic hydrocarbons to bay-region diol epoxides" in <u>Polynuclear Aromatic Hydrocarbons: Chemistry and Biological</u> <u>Effects: Fourth International Symposium</u>, 1979. Bjorseth and Dennis, eds., Battelle Press, Columbus, Ohio, pp267-286.

- Troester, M.A., Lindstrom, A.B., Waidyonatha, S., Kupper, L.L. and Rappaport, S.M. (2002). Stability of hemoglobin and albumin adducts of naphthalene oxide, 1,2-naphthoquinone and 1,4-naphthoquinone. Toxicological Sciences 68: 314-321.
- Tsuda, H., Lee, G., and Farber, E. (1980). Induction of resistant hepatocytes as a possible shortterm *in vivo* test for carcinogens. *Cancer Res.*: 1157-1164.
- Uriah, L.C. and Maronpot, R.R. (1990). "Normal histology of the nasal cavity and application of special application of special techniques." *Environ. Health Perspect.* 85:187-208.
- Waidyonatha, S., Troester, M.A., Lindstrom, A.B. and Rappaport, S.M. (2002). Measurements of hemoglobin and albumin adducts of naphthalene-1,2-oxide, 1,2-naphthoquinone and 1,4 naphthoquinone after administration of naphthalene to F344 rats. Chemico-Biological Interactions 142: 189-210.
- West, J.A.A. et al. (2001). Inhaled naphthalene causes dose dependent Clara cell cytotoxicity in mice but not in rats. *Toxicol. Appl. Pharmacol.*, 173, 114-119.
- Williams, P.R.D. and Paustenbach, D.J. (2002). Risk characterization: Principles and practice. J. Toxicol. Environ. Health. Part B. 5(4): 337-406.
- Wolf, O. (1976). Cancer morbidity amongst chemical workers from a former naphthalene cleaning plant [translated from the German by the UK HSE]. German title: Krebserkrankungen bei Chemiearbeitern einer ehemaligen Naphthalinereinigung] Dt. Gesundh.-Wesen. 31: 996-999. Translation date: June 1995, HSE translation No.: 15358(A).
- Wolf, O. (1978). Carcinoma of the larynx in workers engaged in the purification of naphthalene [translated from the German by the UK HSE]. Zeitschrift fur die gesamte Hygiene und ihre Grenzgebiete, 24 (10), 737-739. Translation date: May, 1995, HSE translation. No.: 15329(A).
- Yu D, Berlin JA, Penning TM, Field J. Reactive oxygen species generated by PAH o-quinones cause change-in-function mutations in p53. Chemical Research in Toxicology 15: 832-842 (2002)

Attachment A

Condensed Transcript National Institute of Environmental Health Sciences National Toxicology Program (NTP) Board of Scientific Counselors

Report on Carcinogens (ROC) Subcommittee Meeting

November 19, 2002

CONDENSED TRANSCRIPT

NATIONAL INSTITUTE OF

ENVIRONMENTAL HEALTH SCIENCES

NATIONAL TOXICOLOGY PROGRAM (NTP)


Board of Scientific Counselors

Report On Carcinogens (ROC) Subcommittee

Meeting


November 19, 2002

Hyatt Regency Bethesda Crystal Ballroom - Baccarat Suites 7400 Wisconsin Avenue Bethesda, Maryland



Pages 53 to 56

13538-1 - NIEHS MEETING - 11/19/02



County Court Reporters, Inc.

Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

TOLL FREE 800.262.8777		Certified Video Techniciana			FAX 540.667.6562	
CCRCCOURTREPORTINGSERVICES.COM		Drofessional Reporting Since 1975			WWW.COURTREPORTINGSERVICES.COM	
STEPHENSON, VA	•	WASHINGTON, DC	٠	LEESBURG, VA	•	HARRISONBURG, VA

Pages 57 to 60

Page 57

1

2

3 4

5 6

7

8

9 10

11

12

13

14

15

16 17

18 19

20

21

22

23

24

25

1 2

3

9

		··· j
is used to prepare chemicals and also used to make sulfonate surfactants.	1 2	background documents indicates the U.S. production of naphthalene pear
Other uses reported for naphthalene	3	around 1968 with the production at
include use as a moth repellant in	4	that time of about 900 million pound
mothballs, and it has been used in the	5	Production decreased, then, into th
past as a deodorant, although our	6	'80s, and by 1982, the production w
current information indicates it may	7	down to about 354 million pounds,
not be used for that presently.	8	in 2000, the production level was
Environmental exposure to	9	reported at 235 million pounds.
naphthalene can come from a number of	10	This particular graph here is
sources, putritive emissions during the	11	showing the consumption of naphth
distillation of naphthalene or the	12	for what we use naphthalene in the
handling of naphthalene in the	13	United States. The vast majority is
preparation of other compounds. Also,	14	used in the preparation of phthalic
the evaporation of naphthalene from	15	anhydride, and the figure here for
mothballs is another major source of	16	2000 is 146 million pounds.
exposure to naphthalene in the	17	Naphthalene sulfonates appear to I
environment.	18	increasing in importance for
It is estimated, based on urban	19	consumption of naphthalene, and y
areas, inhalation exposure	20	can see, over this time period, you
naphthalene, based on an average of	21	can see seems to be ficreasing.
about 1 g/m3, in urban aleas,	22	The use an aphthalengin pesticide
individuals could be exposed to up to	23	appears to be decreasing in this tin
19 g/m3 per day. There is also a	24	period with themse of naphthalene
potential for environmental exposure	25	mother applications remaining fairly
Page 58	- A.	Page 60
dermally to people handling or wearing	1	constant.
clothes that have been stored with	2 3	As far as human cancer studie
mothballs.	3	with naphthalene, there are two cas
Occupational exposure is also		coring studies reported in the

- 4 Occupational exposure is also 5 in the area of ... also done by
- 6 inhalation or dermal exposure. There
- 7 is information that would indicate
- 8 that in the industrial setting,
 - naphthalene is present as both a vapor
- and a particulate, because naphthalene 10
- 11 very readily, and in industry, it has
- been found that usually, if a vapor 12
- 13 and a particulate are present, then
- 14 the concentration of naphthalene as a particulate is higher than it is in
- 15 16 the vapor state.
- 17 The National Occupational 18 Exposure Survey, the latest information we have which I will give you the 19 20 data on, estimates that greater than
- 21 100,000 workers are potentially exposed 22 to naphthalene. 23 This gives you an idea of the
- 24 consumption of naphthalene in the 25 United States. The information

Page 59

es that peaked n at ounds. o the on was ds. and 1S s phthalene the tv is alic or to be nd you /ou ng. icides s time ene in

- udies case 4 series studies reported in the 5 literature. One is laryngeal and other cancer reported in a group of 6 7 dermally exposed workers. This is a 8 report where there are 4 laryngeal cancers plus 1 case each of gastric 9 and colon cancer, and these are a 10 11 cancer cluster that were reported in a 12 group of 6 of 15 distillation plant 13 workers in Germany. 14 The other study is of 15 colorectal carcinoma, and this is 16 reported for a group of men who used 17 Perferal, and this is a medical 18 medicinal used by certain products. 19 Some detail of this particular study. of the 23 cases diagnosed between 1982 20 21 and 1984, there were 11 cases of ... 11 22 of the 23 cases reported were in men 23 who were under 30 years of age. Half 24 the patients with early onset reported 25
 - the use of Preferal which is a

County Court Reporters, Inc. Q[CC

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM Registered Protessional Reporters Certified Video Technicians **Professional Deporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

WASHINGTON, DC LEESBURG VA HARRISONBURG, VA Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

Pages 61 to 64

13538-1 - NIEHS MEETING - 11/19/02

Page 61

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

naphthalene medicinal and was used to treat anal-rectal problems in these cases. The other half of the people where the tumor was observed could not remember if they had used the Preferal or not.

The overall evaluation is that there is insufficient evidence for the evaluation of carcinogenicity in humans based on the human studies.

What we have now is the experimental studies in animals. This is the NTP two-year inhalation study. Groups of male and female V63 Equa mice and Fisher rats were exposed to naphthalene vapor 5 hours...I am sorry...6 hours a day for 5 days a week. The mice were exposed for 104 weeks, and rats were exposed for 105 weeks. The exposure concentration in mice was 0, 10, and 30 ppm, and in rats, the exposure levels were 0, 10, 30, and 60 ppm. In both the rat and the mouse

studies, there was no significant

Page 62

	-
1	effect on body weights of the exposed
2	animals, and survival of the exposed
3	animals was comparable to control
4	animals.
5	A graph of the lung tumors that
6	were observed in the V63 Equa mice,
7	lung tumors were observed in both
8	males and females, and adenomasI'm
9	sorry. These were alveolar
10	bronchiolar adenomas, carcinomas, and
11	adenomas and carcinomas combined.
12	There was a significant increase in
13	adenomas and adenomas or carcinomas
14	combined in the female rats at the
15	high dose levels. There was also a
16	significant positive trend for these
17	particular compounds, both for the
18	adenoma and the adenoma and carcinoma
19	combined.
20	In the males, we saw the same
21	tumors that we saw in the females.
22	However, the incidence of the tumors
23	in the males were within historical
24	control values.
25	So, the NTP concluded that

Page 63

1 there was no evidence of carcinogenicity for naphthalene in the 2 3 male mice and some evidence of carcinogenicity in the female mice 4 5 based on the increased incidence of 6 the adenoma and the adenoma/carcinoma combined in the high dose group. 7 For the rat study, there was 8 9 statistically significant increase in adenomas of the respiratory epithelium, 10 showed a dose related trend, and there 11 were significant increases at all 12 three dose levels. This is a very 13 rare tumor seen in the Fisher rat. 14 15 It was reported at the time that none 16 of these tumors had been seen in any of the historical controls. The 17 pathology description of this tumor 18 was that the was very large ... some of the termors were very large and invasive and even weng hot the olfactory obe of the brain, and I believe it was in one animal in the back decays in one animal in the 19 20 21 22 23 high dose and one animal in the low dose that had metastasis to the lung 24

Page 64

from these particular tumors.

These adenomas were also observed in the female mice, again pointing out that these are very rare tumors, but they were not seen at a significant level.

There were also neuroblastomas observed in both the male and female rats. The neuroblastoma also is a very rare tumor in the Fisher rat.

It was seen at a dose related trend in the males and a dose related trend

in the females and also at a significant level in the high dose

female rats.

So, based on this evaluation, the NTP concluded that there was clear evidence of carcinogenicity in male Fisher rats and also clear evidence of carcinogenicity in the female Fisher rats.

Looking at some of the selected non-neoplastic lesions that were observed, there were chronic...in the mice, there was observed chronic

County Court Reporters, Inc.

12

3

4 5

6

7

8

9 10

11

12 13

14

15

16

17

18

19

20 21

22 23

24

25

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM Registered Professional Reporters Certified Video Technicians Dividentianal Reporting Amor 1975

FAX 540.667.6562 www.courtreportingservices.com

STEPHENSON, VA

WASHINGTON, DC • LEESBURG, VA • H. Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

Pages 65 to 68

Page 67

Page 65

	Page 65			
1 2 3 4 5 6 7 8 9 10 1 12 3 4 5 6 7 8 9 10 1 12 3 4 5 16 7 8 9 21 22 3 4 5 16 7 18 9 20 1 22 3 4 5 25	 inflammation of the nose and lung, hyperplasia of the respiratory epithelium in the nose, and metaplasia of the olfactory epithelium, and all of these non-neoplastic lesions are attributed to naphthalene exposure and the naphthalene. In rats, there was seen atypical basal cell hyperplasia of the olfactory epithelium. This is also a rare observation not reported in other NTP bioassay reports, and this basal cell hyperplasia was observed in anywhere to 88 to 98 percent of the animals that were exposed to naphthalene. In addition, they observed chronic inflammation of the lungs in the males of the Fisher rat, and there was alveolar epithelial hyperplasia in the lungs of the female rats. So, all these non-neoplastic lesions support the neoplastic lesions that were observed in the studies. There are some additional 	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	mouse, and then the animals were held. At weaning, they were separated into groups of 31 male and a group of 16 females, and they were held for a total of 52 weeks. At 52 weeks, the animals were sacrificed, and no tumors were observed in this study. There is another study reported where BDI1 or BDIII3 rats were treated by both intraperitoneal and subcutaneous injections, and animals were treated either intraperitoneal, and another group was treated subcutaneously with 20 mg of naphthalene in oil, and the animals were treated for 40 weeks and then held until they died. For the group of animals that were treated intraperitoneal, they survived for 900 days. With subcutaneous injection mose animals survived for 00 days. The author reported as tumors infains particular study, but the struct is considered inadequate, basically, because of the	
· · · · · · · · · · · · · · · · · · ·	Page 66		Page 68	
1 2 3 4	experimental studies of naphthalene reported in the literature. Some mice were treated. A group of 30 females were exposed to 0, 10, 30 ppm of	1 2 3 4	small number of animals used, and no information was given on the control animals other than the fact that the treated animals survived as long as	

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

controls.

There was also another study

and BDIII3 rats again were used. They

21 animals were treated naphthalene in

days/week and treated for 100 weeks.

After 100 weeks, they were held until

sorry...they survived up to 800 days

authors report it is comparable to the

reported in the literature where BDI1

were treated...I'm sorry. A group of

the feed at 10 to 20 mg/day for 6

they died, and the average ... I'm

which is comparable to the...the

controls. Again, no tumors were

considered inadequate for the low

group and the fact that not enough

number of animals used in the dosing

information on the controls was cited.

As far as genotoxicity, there

observed. This study, again, is

is little evidence of mutagenic

were exposed to 0, 10, 30 ppm of 4 naphthalene for 6 months. Survival in 5 the study was by exposure. The 6 authors reported no significant 7 increase in lung adenomas in this 8 study. There was significant increase 9 in the number of tumors per tumor-10 bearing lung reported in this study, 11 but it was also reported by the 12 authors that the number of tumors per 13 tumor-bearing lung in the controls was 14 significantly lower than in the 15 controls. 16 Other studies on naphthalene 17 18 that have been reported in the literature, IP or subcutaneous studies. 19 There was a study of CD1 mice that 20 were treated intraperitoneal. In this 21 particular study, mice were treated to 22 0.05 molar naphthalene in DMSO in day 23 1, 8, and 5 of life. So, the total 24 dose to these animals was 1.75 M per 25

CCR

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM Registered Professional Reporters Certified Video Technicians Professional Reporting Since 1975

County Court Reporters, Inc.

FAX 540.667.6562 www.courtreportingservices.com

STEPHENSON, VA

WASHINGTON, DC • LEESBURG, VA • HARRISONBURG, VA Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

Pages 69 to 72

13538-1 - NIEHS MEETING - 11/19/02

1 2

3

4

5

6

7

8

9

22

23

Page 69

1	activity for naphthalene. Positive
2	results have been obtained in assays
3	for micronucleus formation, chromosomal
4	aberrations, and chromosomal
5	recombinations in vitro. There is
6	also an in vivo assay reported where
7	oral administration of naphthalene to
8	Sprague-Dawley rats caused oxidative
9	stress and DNA breakage in the liver
10	and brain. In these studies, they
11	were both a single dose experiment
12	where the animals were treated with, I
13	believe it was, 1100 mg/kg as a single
14	dose, and the other was a multiple
15	dose study where the animals were
16	treated with 120 mg/kg/day for 120
17	days, and in both of those studies,
18	the naphthalene caused oxidative stress
19	and DNA breakage.
20	Other relevant data, as ar as
21	absorption and distribution studies of
22	naphthalene, metabolites were found in
23	the urine of workers with algood
24	correlation found between haphthalene
25	exposure and the 1-naphthol exposure

Page 70

	-
1	in their urine. So, it is obviously
2	being absorbed in the workplace.
3	It is also determined to be
4	absorbed through the skin in humans
5	and has been detected in human adipose
6	and breast milk samples. There are a
7	number of animal studies that indicate
8	absorption followingabsorption of
9	naphthaleneexcuse mefollowing
10	oral, dermal, and inhalation exposure.
11	I apologize for the quality of
12	this slide. This is a slide of the
13	metabolism of naphthalene. Naphthalene
14	is metabolized by the p450 enzyme. I
15	put this up here to show that it
16	forms two stereoisomers of the 1,2
17	epoxide, the 1R2S oxide and 1S2R
18	oxide, and these oxides are further
19	metabolized with glutathione. This
20	appears to be the major metabolic
21	pathway for this material.
22	In this slide, I explain it a
23	little more clearly. The naphthalene
24	is bioactivated by the p450 into
25	stereoisomers of the naphthalene 1,2-

Page 71

oxide that I showed previously. It is the 1R2S epoxide or the 1S2R epoxide. There appears to be information in the literature that shows a correlation between the rates of the formation of the 1R2S epoxide and selective toxicity. There is also data reported that the Mouse1 microsome metabolism favors the formation of what I will 10 refer to as the more toxic R-S epoxide, whereas rat and human lung 11 data would indicate that they favor 12 13 the, quote, what I would call the less 14 toxic S-R epoxide. It has also been shown that the 15 rate of metabolism of naphthalene in 16 the mouse lung is about 10 times 17 18 greater than in the rat and about 100 greater than in humans. Other studies have shown that the rat and mouse olfactory epithelium 20 21

favors metabolism to the 1R2S or what I refer to es the more toxic epoxide with the late intering being

approximately half that of the mouse

Page 72

for this particular study in the 1 olfactory epithelium. 2 3 The recommendations that we got for naphthalene, the R21 which is the 4 5 NIEHS recommendation for our Report on 6 Carcinogens recommended that it be 7 listed in the report as reasonably 8 anticipated to be a human carcinogen. 9 The vote on this recommendation was 10 six yes to one no. The one no vote was cast, because that particular 11 12 member felt that the data in the mouse 13 was limited and questioned the relevancy of the nasal tumors in rats 14 15 to humans. The RD2 or the NTP interagency 16 17 Working Group, the other interagency governmental committee that reviews our 18 19 nominations, really did not make a 20 recommendation for naphthalene. We 21 had a very intensive discussion. 22 There was a motion to list naphthalene as being reasonably anticipated to be 23 24 a human carcinogen, and there were 25 four yes votes to that motion and four

County Court Reporters, Inc.

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM Registered Professional Reporters Certified Video Technicians Drofessional Deporting Since 1975

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

WASHINGTON, DC LEESBURG, VA Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

Pages 73 to 76

13538-1 - NIEHS MEETING - 11/19/02

Page 75

Page 73

1	no votes, the no vote being for the	1	we could pass it around to members of
2	same reason that the RD1. These	2	the committeesubcommittee.
3	members felt that the data were	3	DR. SMITH: It has been
4	limited in mice and the relevancy of	4	suggested that we take a little break
5	the tumors in rats to humans.	5	now to go traveling through that way
6	Another motion was made not to	6	and also to get copies of
7	list naphthalene in the Report on	7	thedistributed so that we can have
8	Carcinogens, and that also resulted in	8	a quick look at that. So, can we
9	a 4:4 tie. So, the RD2 felt that	9	take a little
9 10	they should go forward with no	10	DR. FROINES: My
11	recommendation or could not make a	11	comments also were given this morning
12	recommendation for this particular	12	so that I will be going through them,
13	combination.	13	so, during the break, you should read
14	I would also mentionI don't	14	them.
14	have this on the slide, but I would	15	DR. SMITH: Let's take a
16	also mention that the IARC has	16	10-minute break.
17	recently reviewed naphthalene. The	17	(WHEREUPON, a brief recess was taken.)
18	monograph on naphthalene should be	18	DR. SMITH: Ready to
10	published very early in 2003, but they	1.9	stanlagaji? Have had distributed
20	have indicated on their website a	20	the summary of the Inclocument, and it
20	summary of the review, and I believe	21	is available on the table over there
22	that summary indicates that the IARC	22	if you want to see it. With that,
22	found that there was sufficient	23	the written comments as the
23	evidence of carcinogenicity in	24	naphthalene parter of the American
25	laboratory animals and that they	35 Makes	Chemistry Council, and they have been
20			
_	Page 74		Page 76
	- -		distributed to all autoammittee

			distributed to all subcommittee
1	propose to list it as a Group 2B		
2	possible human carcinogen. I believe	2	members. In addition, there is a
3	that information is available on their	3	request to make an oral presentation
4	web site.	4	by Dr. Vincent Piccarillo on behalf of
5	Public comments, we received a	5	the ACC naphthalene panel. Is Dr.
6	number of public comments. The	6	Piccarillo here?
7	American Chemistry Council submitted an	7	SPEAKER: Yes.
8	extensive comments on the nomination	8	DR. SMITH: Thank you.
9	and also the background document, and	9	DR. CARPENTER: Let me
10	these comments were supported by the	10	ask a question before he starts
11	American Coke and Coal Chemical	11	regarding the presentation before the
12	Institute, Honeywell Commercial	12	break.
13	Systems, Industries, and Riley Industry	13	DR. SMITH: One moment.
14	Reports.	14	Wemaybe I didn't allow time for
15	DR. SMITH: Thank you,	15	people to ask questions about the
16	Dr. Jameson. Questions from the	16	DR. CARPENTER: The
17	subcommittee?	17	previous presentation.
18	(No response.)	18	DR. SMITH: Yes,
19	DR. SMITH: There being	19	presentation by Dr. Jameson. Yes, Dr.
20	none	20	Carpenter?
	DR. FROINES: Just one	21	DR. CARPENTER: 1 am
21	comment. I am going to be discussing	22	curiouswhen I read the document, I
22	a document that I wrote on naphthalene	23	noticed the presence of carcinomas in
23		24	males versus females, and there is
24	later, but I have the IR review		what appeared to me, at least, to be
25	abstract, and I would appreciate it if	25	what appeared to me, at least, to be
		<u> </u>	

County Court Reporters, Inc. CCR

•

TOLL FREE 800.262.8777 CCRCCOURTREPORTINGSERVICES.COM

٠

Registered Protessional Reporters Certified Video Technicians **Drolemont Deporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

HARRISONBURG, VA

.

STEPHENSON, VA

LEESBURG, VA WASHINGTON, DC Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

Pages 77 to 80

13538-1 - NIEHS MEETING - 11/19/02

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

20

21

22

23

Page 77

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

25

a fairly high number of carcinomas in the male. I see no statistical analysis other than the fact that there is no trend, and the results appear to be disregarded in the writeup based on the fact that it fell within historical controls, carcinomas that are typically seen. Could I have maybe a little clarification about the thought that goes into ... the thought process that is involved in that? It seems like, to me, when I

see a zero in a control group and then 3 and 7 carcinomas in the treated groups, that looks like that might be at least a finding which should be considered.

DR. SMITH: Dr. Jameson? DR. JAMESON: DL Carpenter, I think that will prove to be a very critical aspect of the board's, that they might suggest that we defer that question a lifte bit until after we finish all the presentations.

Page 78

1	DR. CARPENTER: As long
2	as we get an answer, okay.
3	DR. SMITH: Okay, let's
4	do that. Dr. Piccarillo? Thank you.
5	DR. PICCARILLO: Good
6	morning. On behalf of the naphthalene
7	panel of the American Chemistry
8	Council, we appreciate the opportunity
9	to speak to you this morning about
10	naphthalene. The assessment of the
11	carcinogenic potential and the
12	classification for naphthalene clearly
13	requires an understanding of both the
14	genotoxicity of the molecule as well
15	as its inter-species metabolism. Both
16	genotoxicity and metabolism have been
17	extensively published in the
18	literature, and this work continues
19	today.
20	Dr. Jameson covered, really, a
21	lot of the points I had planned to
22	discuss today, so I will briefly go
23	over the points that I think are very
24	important.

important.

In your discussions regarding

Page 79

naphthalene, there are four major issues that need to be considered. The first, of course, is that naphthalene is not likely to be a genotoxic carcinogen. There is no evidence of mutagenicity in short-term tests, and naphthalene does bind proteins; however, it does not appear to be DNA active. Secondly, species and site selectivity in rodents correlates with the susceptibility to cytotoxicity, and the cytotoxicity, in turn, appears to be related to the risk of naphthalene metabolism to the epoxide. The third item is the kinetics of metabolism in rats and mice really don't differ. However, when we take a Book at the human example, the activity in the rodent stacies is more than 100 fold rate of that seen in human cells.

Next alease. The last item is that metabolisis in aphthalene in 1 microsomes from primates is at least

Page 80

	-
1	an order of magin primates and
2	monkeys is at least an order of
2 3	magnitude lower than any rodent
4	species tested and 100-fold lower than
5	that in mice.
6	Next, please. As I mentioned,
7	the first issue is the genotoxicity of
8	naphthalene. The weight of the
9	evidence clearly shows that naphthalene
10	is not genotoxic.
11	In Dr. Jameson's presentation,
12	he did discuss a few positive findings
13	that were seen in literature studies.
14	However, an overall review of the
15	published literature shows that there
16	are nearly 40 mutagenicity studies
17	that have been conducted with
18	naphthalene.
19	When you take a look at that
20	number, there are 33 non-mammalian and
21	mammalian in vitro assays that gave
22	negative results, there are 4 in vivo
23	assays which also were negative, and
24	when you take a look at that weight
25	of evidence versus the few positive

County Court Reporters, Inc.

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM

٠

Registered Protessional Reporters Certified Video Techniciana **Drofessional Deporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

WASHINGTON, DC LEESBURG, VA HARRISONBURG, VA

Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

Pages 81 to 84

13538-1 - NIEHS MEETING - 11/19/02

23

24

Page 81

	-
1	studies, clearly, the weight of
2	evidence shows that we are not dealing
3	with a genotoxic carcinogen here, that
4	there must be an epigenetic mechanism
5	at play in the induction of tumors.
6	Hopefully, some of the data I will
7	show you today will demonstrate that
8	that mechanism relates to the
9	differential metabolism between
10	species.
11	Species and site selectivity
12	and cytotoxicity is very important.
13	Next, please. This table summarizes
14	the results on various tissues upon
15	oral administration of naphthalene at
16	doses approaching the LD50 for both
17	the mouse and the rat. The
18	cytotoxicity was measured by
19	histological evaluation of specific
20	tissues.
21	As you can see in the mouse,
22	the majority of findings were in the
23	bronchioles with other findings being
24	located in the trachea. In the rat,

25

Page 82

however, cytoxicity was not observed

	_
1	in the lung tissues per se, and the
2	majority of the findings, pathological
3	findings, were limited to the
4	olfactory epithelium. In the mouse,
5	olfactory changes were noted only at
6	the highest dose.
7	This clearly shows that there
8	is some species sensitivity for
9	specific tissue.
10	Next. Dr. Jameson covered the
11	metabolism of naphthalene to some
12	extent, but this elaborates the
13	metabolism a bit more. Of course, we
14	are starting with the parent molecule,
15	naphthalene, and as he noted, the
16	mouse lung favors the formation of the
17	1R2S oxide and moves to what, for the
18	particular purposes that you are going
19	to see in the following slide, the
20	formation of conjugate 2. In the rat,
21	hamster, and monkey lung, however, the
22	predominant metabolism goes through the
23	1S2R oxide with the formation,
24	subsequently, of conjugate 1 and
25	conjugate 3.

Page 83

Another point that is very 1 important is that in the mouse, there 2 3 is a great deal of specificity for cytotoxicity in the Clara cell in the 4 5 lungs, and it appears that the mechanism involves the formation of 6 the 1R2S oxide with an interaction 7 with proteins by some mechanism which 8 is vet undefined to induce Clara cell 9 10 toxicity. Next, please. In the olfactory 11 tissues, however, in the nasal 12 epithelium, we do see a difference in 13 the metabolism from that of the lung. 14 In the olfactory epithelium for both 15 the mouse and the rat, the predominant 16 metabolism follows the pathway of the 17 1R2S that it follows in the 18 predominant pathway in the lung of the mouse. 20 So, agross these species, it appears that we have the same pattern 21 22

of metabolism occurring in the nasal epithelium White as I said, is different from that of the lung, but

Page 84

	1	the point that you need to note is
	2	that even though the patterns are
	3	similar, the amount of metabolism, the
	4	rate of metabolism in the mouse is
	5	double that of the rat.
	6	But a key issue that has to be
	7	looked at, too, is the fact that, as
	8	we have said, the metabolism in the
	9	rat nasal epithelium is clearly
	10	different from that seen in the lung,
	11	and when we take do a comparison of
	12	the conjugate 2or, excuse me,
ĺ	13	conjugate 3 from the 1R2S metabolism
	14	compared to the amount of metabolism
İ	15	that is conjugates 1 and 3 from the
	16	1S2R metabolism, the rate of
ŀ	17	metabolism through the alternate
I	18	pathway is about 36 fold greater than
	19	that through the normal metabolism
	20	pattern seen in the lung of the rat.
	21	The kinetics of metabolism of
	22	naphthalene by recombinant SIP2F from
	23	the rat and the mouse do not differ.
	24	However, when you take a look at human
l	25	tissuesand Dr. Buckett's laboratory
1	20	loodoodha br. buokotto laboratory

County Court Reporters, Inc. CCD

.

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM Registered Protessional Reporters Certified Video Technicians **Professional Reporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

WASHINGTON. DC Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

LEESBURG, VA

Pages 85 to 88

13538-1 - NIEHS MEETING - 11/19/02

1 2

3

4

5

7

24

2号

Page 85

1	at UC-Davis has done a lot of work
2	with human lung tissuediscovered
3	that the activities in the human lung
4	for 2F1 are more than 1000-fold lower
5	than that seen in the rodent species.
6	Again, if you are looking at a
7	mechanism related to the metabolism,
8	clearly, the human is substantially
9	different from that of the rodent
10	species, at least for the lung.
11	Next, please. The SIP2R forms
12	among species appear to have quite a
13	few similarities in regards to the
14	amino acid sequence, and this slide
15	just shows the numbers of amino acid
16	sequences that are comparable among
17	the species.
18	Next, please. This table
19	summarizes the activity of the
20	recombinant proteins from the mouse,
21	the rat, and the human. Again, in
22	looking at the V maxis he te , you can
23	see there is a substantial difference
24	in the enzyme activities when you

25

compare the human to the two rodent

	Page 86	
1	species.	
2	Next, please. The metabolism	
2 3	of naphthalene through primates,	
4	including both the monkey and the	
5	human, is an order of magnitude slower	
6	than any rodent species tested and 100	
7	times slower than that in the mouse.	
8	Current research is ongoing at	
9	this point in looking at the rate of	
10	naphthalene metabolism using primate	
11	olfactory epithelium tissue. We	
12	anticipate that because of the fact	
13	that we do see such large differences	
14	in the metabolism which appears to	
15	relate to the cytotoxicity of the lung	
16	that similar findings in the olfactory	
17	epithelium would be very germane to	
18	the evaluation of the potential for	
19	cancer risk in humans. That is, if	
20	we see the same lower potential for	
21	metabolism of naphthalene to whatever	
22	cytotoxic chemical there is being	
23	formed that this may, indeed, show	
24	that the type of olfactory tumors that	
25	we see in the rat may be, again, a	

Page 87

specific type of tumor for that particular species, and, as has been mentioned earlier, these nasal tumors may not be relevant to man anyway. The work that we talked about 6 in the monkey is currently being conducted at UC-Davis, and we expect that the results of these studies will 8 be available in approximately one 9 10 year. I have seen some of the unpublished data from the literature, 11 but I feel it is inappropriate to 12 discuss those unpublished results 13 today, but I would hope that, at 14 15 least, this group would take that into consideration that there are 16 17 significant data still being generated on the metabolism of naphthalene in 18 the primate species Next To conclude, as we have 20 discusses it appears that the tumors 21 in the mouse appear to be species-specific and related somehow to the 22 23

Page 88

metaboli pathway which ultimately may

lead to cytotoxicity as demonstrated

1	by the destruction of the Clara cell
2	in the mouse lung. The nasal tumors
3	in rats, we feel, are also likely a
4	result of cytotoxic injury, and that
5	cytotoxic injury is a result of the
6	metabolism that is occurring in the
7	olfactory epithelium. We have shown
8	some of the data here, and as I have
9	said, we are also looking at the
10	humanexcuse meprimate, and,
11	hopefully, we will get to the human
12	tissue to demonstrate that these
13	differences may be a species-related
14	effect.
15	All of the previous study and
16	all of the studies that we have seen
17	in the literature strongly support a
18	conclusion that there is a correlation
19	between the rate of metabolism and the
20	cytotoxicity seen in the animal
21	species and that there are substantial
22	differences in the rates of metabolism
23	in the rodent and the primate models.
24	Again, these are major considerations
25	that you need to consider in your

County Court Reporters, Inc. ^{1}CD

(

TOLL FREE 800.262.8777 CCROCOURTREPORTINGSERVICES.COM Registered Professional Reporters Certified Video Techniciana **Drofessional Deporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

WASHINGTON, DC LEESBURG, VA Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22856

Pages 89 to 92

13538-1 - NIEHS MEETING - 11/19/02

Page 89

1 deliberations. 2 It was mentioned that 3 naphthalene went before an IARC panel 4 back in February, and I have not seen 5 the summary that has come out of that, 6 although I was in Leon at the time of 7 the meeting and knew much of what 8 happened in those deliberations, and 9 the panel there had many of the same problems that the RG1 and the RG2 had 10 in Canada, and that is looking at the 11 metabolism and looking at the 12 13 relevance of the lung tumors and the nasal tumors to human carcinogenesis. 14 15 And I know that it is going to be quite a bit of deliberation for 16 this group to bring these issues to 17 closure, and I feel that if you should 18 need any further information, the 19 20 naphthalene panel will be more than 21 happy to provide it to you.

> Thank you. DR. SMITH: Thank you, Dr. Piccarillo. Any questions from the

22

23

24

25

Page 90

1	subcommittee for Dr. Piccarillo?	
2	(No response.)	
3	DR. SMITH: Well, thank	
4	you very much for your presentation.	
5	Any other comments from those	
6	present, public comments?	
7	(No response.)	
8	DR. SMITH: Well, let's	
9	proceed now to the formal reviews. 1	
10	think the first reviewer for this is	
11	Dr. Carpenter.	
12	DR. CARPENTER: Again,	
13	everybody has copies of my comments	
14	that are in front of you. It looks	
15	like some of my symbols didn't	
16	transpose entirely accurately, but what	
17	I will do is summarize what I thought	
18	when I finished the review.	
19	I think that there is more than	
20	sufficient information to determine if	
21	exposure is really an issue with	
22	naphthalene. Its industrial uses with	
23	their occupational exposures or the	
24	chance for occupational exposures are	
25	hiah	

Page 91

DR. SMITH: Excuse me. 1 2 Can you sit closer to the mic or ... 3 DR. CARPENTER: I have 4 too much junk in front of me. 5 There is the potential for 6 environmental exposure. Naphthalene is 7 an environmental contaminant. I note 8 here that APSBR has reported 9 naphthalene as present in over a third of the Superfund sites that have been 10 reported in the United States, so 11 12 there is both occupational and 13 environmental exposures. 14 Relative to carcinogenicity, I 15 feel it is clear that naphthalene is 16 carcinogenic in rats, and although the 17 evidence is equivocal, naphthalene is 18 also carcinogenic in mice, and I am sure there will be a lot more discussion about that, so I will just let it go a that. 20 21 I agree with the fact that the hetero for a given toxicity is fairly limited, but there is good evidence 22 23 24 that naphthatene does cause oxidative

Page 92

1	stress and DNA damage, resulting in
2	the potential for toxic mechanism.
3	I think thatwell, I have a
4	statement here that the well-documented
5	differences in response to naphthalene
6	are likely due to species differences
7	in anatomy and physiology that were
8	just presented to us, but the
9	importance of these factors in the
10	carcinogenic response is not to this
11	knowledge. It seems clear to me that
12	naphthalene is a threshold carcinogen,
13	and I think it is likely that we
14	don't see more tumors, because we just
15	are not reaching the levels that are
16	carcinogenic in humans.
17	Epidemiological evidence linking
18	naphthalene to cancer in humans is
19	poor, but there doesn't appear to be
20	any mechanistic reason why naphthalene
21	wouldn't be carcinogenic in humans,
22	provided the exposures were sufficient.
23	And I think that is a real key here
24	that we are dealing with in the
25	exposure-related issue.

County Court Reporters, Inc. q_{1}

•

(

WASHINGTON, DC

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM

.

Registered Prolessional Reporters Certified Video Technicians **Professional Deporting Since 1975**

FAX 540.667.6582 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

LEESBURG VA

Pages 93 to 96

13538-1 - NIEHS MEETING - 11/19/02

Page 93

1	I think that some of the
2	comments that were made in the
2 3	material that was presented to us make
4	that same argument. The EUSCOEL
5	proceedings speculate that if you
6	avoid exposure and avoid cytotoxicity
7	that you avoid carcinogenicity. I
8	think that is a good argument for a
9	dose-response relationship,
10	biomechanistic relationship.
11	I think what we are dealing
12	with here with this review is we are
13	talking about hazard ID. The fact is
14	that I have seen nothing in this
15	review that indicates that humans
16	don't have the same mechanisms that
17	the rodents do. So, I think that
18	this document, the strength of the
19	information, is for hazard ID and that
20	the real problem that we are faced
21	with is strength of exposures, and
22	that will be a real problem for people
23	who have to do risk assessment
24	analysis for this material based on
25	the carcinogenicity of it.

Page 94

1	I voted to list as reasonably
2	anticipated to be a human carcinogen.
2 3	DR. SMITH: Thank you,
4 5	Dr. Carpenter. Next is Dr. Frumpkin.
5	DR. FRUMPKIN: Thanks.
6	I'll echo a lot of what Dr. Carpenter
7 8	said, so I'll be very brief.
8	We do have exposure. I think
9	the human evidence that is available
10	isn't helpful, so we are going to be
11	considering the animal evidence
12	predominantly in our discussions.
13	I saw the same results that you
14	all saw and thought hard about the
15	comments in terms of different
16	preferences for metabolic pathways in
17	the different species that have been
18	observed, about the changes in nasal
19	anatomy between rodents and humans,
20	about the role of prior tissue
21	inflammation before the development of
22	tumors, and I didn't see anything that
23	gave me reassurance that they should
24	notthat there would not be a
25	carcinogenic effect in humans, although

Page 95

1	I think that, as Dr. Carpenter said,
2	that the question of dose is extremely
3	important here.
3 4	So, for those reasons, I, too,
5	voted to list as reasonably
6	anticipated to be a human carcinogen.
7	DR. SMITH: Thank you.
8	Dr. Roberts?
9	DR. ROBERTS: Thank you.
10	I concur with the previous comments
11	about exposure. There were some
12	comments from that naphthalene panel
13	that perhaps in the background
14	document overestimated the number of
15	workers that are currently exposed,
16	but that may well be the case. I
17	suppose they are probably in as good a
18	position as anyone to know how many
19	workers are exposed. I think perhaps
20	that should be corrected in the
21	background document, but it would be
22	very user for that purpose if there
23	were sorth-kind of formal documentation
24	that the the Person use or cite in
25	terms of the number of workers that

Page 96

Luge Se	
are currently exposed.	
individuals exposed. So, I think in	
an important issue. Clearly, we have	
sufficient exposure.	
descriptors again being placed on	
those studies.	
In trying to sort out whether	
or not that was enough, in other	
species, I looked for some precedent.	
It would be very helpful to me if	
	But there doesn't seem to be any disagreement that there is abouta sufficient number of individuals exposed. So, I think in terms of listing criteria, this is not an important issue. Clearly, we have sufficient exposure. This, for me, was a tough call in terms of recommending listing or not listing, and as I looked at the issue of whether or not there is a response in multiple species, it seems to me that we have clear evidence in both genders in rats, evidence in male mice, some evidence in female mice, and I agree, I think, with those descriptors again being placed on those studies. In trying to sort out whether or not that was enough, in other words, some evidence in mice was enough to qualify for multiple species, I looked for some precedent.

County Court Reporters, Inc. CR (

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM

•

Registered Professional Reporters Certified Video Technicians **Professional Deporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

HARRISONBURG, VA WASHINGTON, DC ٠ LEESBURG, VA ٠ Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

Pages 97 to 100

13538-1 - NIEHS MEETING - 11/19/02

Dago 07

	Page 97		Page 99
1	people could even say oh, this is just	1	pathologists on the panel and other
2	like such and such a compound where we	2	folks that have
2	had the same kind of level of evidence	3	DR. SMITH: Those are
4	and there was a vote to list or a	4	the three primary reviewers. Also,
5	vote not to list, so I looked for	5	Dr. Froines has prepared a brief
6	some guidance or precedent but,	6	document which is distributed and on
7	unfortunately, couldn't find any.	7	which I would invite him to speak to
8	I then went about sort of	8	you now.
9	looking through the 9th Report on	9	DR. FROINES: You may
10	Carcinogens and what is available on	10	have made one mistake; it may not be
11	the 10th and tried to look at the	11	entirely brief, but
12	evidence for those as well as looking	12	I'll start out with the
13	about for other chemicals that have	13	conclusion that, basically, I think
14	roughly the same kind of evidence for	14	that naphthalene meets the criteria
		15	under number 3 to an unusual degree
15	carcinogenicity as exists now for	15	with regard to incident site or tumor
16	naphthalene. By that, I don't mean	17	or age of onset with respect to the
17	that exactly, but, I mean, for clear evidence for both genders in one, some	18	animalto the rat studies.
18	evidence for both genders in one, some evidence in the other species little	19-	think ther than ouse work is
19 20	or no evidence for genotoxienty, and	20	extremel interesting this not
20	insufficient evidence for human	20	extremel anteresting. This not fully sufficient, I think, but it is
22	carcinogenicity, and there is a	22	certainly upportive. So I would
22	handful of chemicals that the into	23	argue that it is supportive.
-	those criteria. None of themes	23	Lwood and argue that
24 25	listed.	25	maphthalene belongs to an agent,
25	listed.	20	hapitulaiene belongs te en agent,
	······································		· · · · · · · · · · · · · · · · · · ·
	Page 98		Page 100
1	Now, I realize that is not a	1	substance, or mixture which belongs to
1 2	Now, I realize that is not a perfect argument for what is	2	substance, or mixture which belongs to a well-defined structurally-related
	Now, I realize that is not a perfect argument for what is automatically nominated for listing,	2	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that
2 3 4	Now, I realize that is not a perfect argument for what is	2 3 4	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that
2 3	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are	2 3 4 5	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic
2 3 4	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I	2 3 4 5 6	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody
2 3 4 5	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are	2 3 4 5 6 7	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have
2 3 4 5 6	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same	2 3 4 5 6 7 8	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their
2 3 4 5 6 7	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of	2 3 4 5 6 7 8 9	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity.
2 3 4 5 6 7 8	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really	2 3 4 5 6 7 8 9	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this
2 3 4 5 6 7 8 9	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of	2 3 4 5 6 7 8 9 10 11	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more
2 3 4 5 6 7 8 9 10	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on	2 3 4 5 6 7 8 9 10 11 12	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe
2 3 4 5 6 7 8 9 10 11	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my	2 3 4 5 6 7 8 9 10 11 12 13	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall
2 3 4 5 6 7 8 9 10 11 12	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on	2 3 4 5 6 7 8 9 10 11 12 13 14	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with
2 3 4 5 6 7 8 9 10 11 12 13	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about and I would like to hear from other	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some comments at the outset. One, I think
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about and I would like to hear from other members of the panel is whether or not	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some comments at the outset. One, I think thisthe reason I wanted to step
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about and I would like to hear from other members of the panel is whether or not the rat nasal tumor response is	2 3 4 5 6 7 8 9 10 11 12 13 4 15 16 7 18 19	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some comments at the outset. One, I think thisthe reason I wanted to step down as chair and make these comments
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about and I would like to hear from other members of the panel is whether or not	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 7 18 9 20	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some comments at the outset. One, I think thisthe reason I wanted to step down as chair and make these comments was because I considered naphthalene
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about and I would like to hear from other members of the panel is whether or not the rat nasal tumor response is	2 3 4 5 6 7 8 9 10 11 12 13 4 15 6 7 8 9 10 11 21 3 4 5 6 7 8 9 10 11 23 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 11 2 11 2 11 2 11 2 11 2 11 2	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some comments at the outset. One, I think thisthe reason I wanted to step down as chair and make these comments was because I considered naphthalene to be a particularly important
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about and I would like to hear from other members of the panel is whether or not the rat nasal tumor response is sufficient unusual to qualify on that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 6 7 8 9 10 11 23 14 5 6 7 8 9 10 11 23 20 21 22	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some comments at the outset. One, I think thisthe reason I wanted to step down as chair and make these comments was because I considered naphthalene
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about and I would like to hear from other members of the panel is whether or not the rat nasal tumor response is sufficient unusual to qualify on that basis. Is the nasal tumor	2 3 4 5 6 7 8 9 10 11 12 13 14 15 6 7 8 9 10 11 12 13 14 5 6 7 8 9 10 11 22 23	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some comments at the outset. One, I think thisthe reason I wanted to step down as chair and make these comments was because I considered naphthalene to be a particularly important compound. I direct an air pollution research center in southern California,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 7 8 9 20 21	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about and I would like to hear from other members of the panel is whether or not the rat nasal tumor response is sufficient unusual to qualify on that basis. Is the nasal tumor sufficiently unusual that that then	2 3 4 5 6 7 8 9 10 11 12 13 14 15 6 7 8 9 10 11 23 14 5 6 7 8 9 10 11 23 20 21 22	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some comments at the outset. One, I think thisthe reason I wanted to step down as chair and make these comments was because I considered naphthalene to be a particularly important compound. I direct an air pollution
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Now, I realize that is not a perfect argument for what is automatically nominated for listing, but as I step back and look at it, I see that, you know, there are chemicals with essentially the same kind of weight of evidence that aren't in the list; chemicals that are on the list have stronger weights of evidence. So, that really significantly diminished my enthusiasm for listing this chemical based on multiple species, and, in fact, my preliminary recommendation was not to list. The piece that I am not about and I would like to hear from other members of the panel is whether or not the rat nasal tumor response is sufficient unusual to qualify on that basis. Is the nasal tumor sufficiently unusual that that then becomes essentially the pivotal	2 3 4 5 6 7 8 9 10 11 12 13 14 15 6 7 8 9 10 11 12 13 14 5 6 7 8 9 10 11 22 23	substance, or mixture which belongs to a well-defined structurally-related class of substances, and in that regard, I would suggest that naphthalene is a two-ringed polycyclic aromatic hydrocarbon, and as everybody in this room knows, PAHs have relatively strong evidence as to their carcinogenicity. In addition to thatand this is what I will come to in my more prepared commentsthe naphthoquinones, I think, also fall into a class of compounds with documented toxicity. Now, I wanted to make some comments at the outset. One, I think thisthe reason I wanted to step down as chair and make these comments was because I considered naphthalene to be a particularly important compound. I direct an air pollution research center in southern California,

County Court Reporters, Inc. CCR

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM

•

Registered Protessional Reporters Certified Video Technicians Drofessional Deporting Since 1975

٠

FAX 540.667.6562 WWW.COURTREPORTINGSERVICE8.COM

٠

STEPHENSON, VA

WASHINGTON, DC LEESBURG, VA HARRISONBURG, VA Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

Pages 101 to 104

13538-1 - NIEHS MEETING - 11/19/02

Page 103

Page 104

Page 101

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	concentrations are about 0.95 g/m3. In Los Angeles, we have the best of everything, of course, and we get up to about 6 g/m3, but even at 0.95 g/m3 for which most of you probably don't have a reference point, I just wanted to tell you that if you compare that concentration of naphthalene with the concentration, for example, of benzoyl pyrene, the differences are a factor of 10,000. In other words, the concentration of naphthalene in Los Angeles air is 104 times as great as the concentration of the otherof larger-ring PAHs.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	with or without exogenous metabolic activation or in human cell lines with inherent metabolic capabilities, suggesting that a single hit linear model of carcinogenesis is unlikely. That is not our role. It is not our role to decide whether or not a single hit linear model of carcinogenesis is the issue before us. So, I think that we needand I should say, parenthetically, that that sentence is incorrect, and I'll come to that. I think Ron Melnick from NISH wrote a very nice paper recently on
	larger-ring PAHs.		wrote a very nice paper recently on
16	So, what we have in urban areas	16	the role of epoxides, and I won't
17	is an issue of public health	17	belabor you with his comments. I
18	significance precisely because the	18	quoted them in my document, but,
19	concentrations of the vapor phase and	19	clearly, Arring oxide formation,
20	partial-bound naphthalene is extremely	20	epoxide formation, there is significant
21	high. So, it certainly meets the	21	evidence for carcinogenicity associated
22	exposure criteria and puts a burden on	22	with that those intermediates, as a
23	us to take this one very, very	23	result of RAS and p55 mutations, and
24	seriously.	24	I think people to this room are aware
25	The second comment I wanted to	25	wof that, and don't need to emphasize

Page 102

	rage 102		rage 104
1	make is on both the presentations this	1	that.
2 3	morningand Dr. Carpenter alluded to	2 3	What I wanted to do was to
3	thisI found them, at some level,	3	spend some time talking about
4	speculative, and I found them	4	metabolic pathways, because I don't
5	speculative insofar as they argue	5	think it has been adequately dealt
6	about the metabolic differences, and I	6	with. One of the things I think is
7	know Allan Buckett very, very well,	7	clear is that in humans, in the urine
8	and I have interacted with him over	8	of humans, 1-naphthol, 2-naphthol, 1,2-
9	the years on a number of occasions and	9	naphthoquinone, and 1,4-naphthoquinone
10	respect his work, and I think the work	10	have been reported in the urine of
11	is important.	11	humans. In addition to the naphthols,
12	However, in the context of this	12	1,2-dihydronaphthalene diol was a
13	discussion, we are attempting to	13	stable intermediate produced from human
14	identify the compound; we are not	14	microsomal lung tissue. All these
15	conducting a risk assessment. So, we	15	derive from the initial metabolism of
16	need to be very careful to	16	naphthalene into A-ring oxide.
17	differentiate risk assessment data from	17	Now, I wanted I want you, if
18	more qualitative information.	18	you would, to look at the document
19	And I will read you one thing	19	that I prepared, to look at the
20	from one of the submitted comments.	20	figures on the last page, and you will
21	It says, Results of extensive studies	21	see something that wasn't emphasized
22	of genotoxicity by standard methods	22	in the other presentations about the
23	demonstrate that naphthalene and	23	metabolism of naphthalene. From the
24	naphthoguinone do not induce point	24	most recent speaker, you will notice
25	mutations in vitro in bacterial cells	25	the dihydro diols here going to

County Court Reporters, Inc.

TOL1 FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM

٠

Registered Protessional Reporters Certified Video Technicians **Professional Deporting Since 1975**

CD. (

> FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

WASHINGTON, DC LEESBURG, VA Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

HARRISONBURG, VA

Pages 105 to 108

1

2

3

4 5

6 7

8

9

10

11

12

13

14

15

16

17

18

Page 107

I won't take time, because, presumably, most of you are aware of

example of the reaction of the orthoquinone, 1,2- compound, with DNA, and

you can see 1:56:05 formation, and

then there is the modifications that

So that this pathway is

to the present has been on the

it seems to me that a primary

occur from reactive oxygen species.

extremely important when we consider naphthalene, and all the emphasis up

formation of the oxides when, in fact,

naphthalene is by the quinone. Within

nutagent in the Ames test. They are mutagent in the Ames test. They are mutagent in four test restraints, TA97a, T4100, TA104 and TA98. The 2-methyl derivative which most people

know as meta-dione has also been shown

mechanism for carcinogenicity of

that context, let me just discuss

briefly some of the other factors.

that, but in this case, this is an

activity on the other.

Page 105

1	quinone, but he didn't emphasize that
2	very much.
	DR. PORTIER: Dr.
3 4	Froines, could we have a copyyou
5	have an overhead for that, do you not?
6	DR. FROINES: I think
7	so. To find it would be a
8	majorit's probably down there by
9	myI wanted to emphasize here a
10	pathway that I consider to be
11	extremely important with respect to
12	the carcinogenicity of naphthalene,
13	namely, that the dihydro diol that is
14	formedand there is no argument
15	about that. It is a major metabolite.
16	It is found in microsomes; it is found
17	in humansthat a principal pathway
18	is through the catalytic activity of
19	dihydro diol, the hydrogenase, which
20	takes you to a catechol, and the
21	catechol is subsequently primed the
22	PAH quinone.
23	Not only that, but it has been
24	mentioned by others that this semi-
25	quinone, quinone redox cycling process

	Page 106		Page 108
1 2	results in oxidative stress with the reduction of molecular oxygen to	1 2	to be mutagenic. We have quantitatively
3	superoxide anion radical with	3	documented the generation of reactive
4	subsequent Benton type chemistry going	4	oxygen species from both the 1,2- and
5	to hydrogen peroxide and a hydroxyl	5	1,4-naphthoquinone.
6	radical, so that this pathway with	6	And let me read to you from a
7	naphthalene is extremely important.	7	paper from Penning from 2002. Penning
8	In our laboratories, we have	8	has argued that one of the most
9	been studying the quantitative	9	commonly mutated genes in lung cancer
10	formation of reactive oxygen from the	10	is a p53 tumor suppressor gene with a
11	naphthoquinones, and you find one	11	preponderance of T to t transversions
12	molecule of a 1,2- or 1,4-	12	which he argues is a signature
13	naphthoquinone will produce tens of	13	mutation. In a yeast reporter system,
14	thousands to hundreds of thousands of	14	Penning demonstrates greater than 46
15	molecules of reactive oxygen, because	15	percent mutations in p53 where GC-TA
16	the naphthoquinones act catalytically.	16	transversions from the naphthalene
17	They don't act stoichiometrically.	17	metabolite 1,2-naphthoquinone. Their
18	They also undergo 1,4-	18	conclusion is PAH ortho-quinones act
19	microedition reactions in which they	19	as endogenous mutagens leading to p53
20	act as electrophiles and will bind	20	mutations.
21	with DNA as electrophiles. So, you	21	So, the argument that
22	have two pathways that are possible,	22	naphthalene is not genotoxic is simply
23	the catalytic activity through the	23	not true unless one decides to
24	formation of reactive oxygen species	24	eliminate or not take into
25	on the one hand and the electrophillic	25	consideration the products of

County Court Reporters, Inc. QDT

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM Registered Protessional Reporters Certified Video Technicians **Drofessional Deporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

HARRISONBURG, VA ٠ LEESBURG, VA WASHINGTON, DC Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

Pages 109 to 112

13538-1 - NIEHS MEETING - 11/19/02

Page 111

Page 109

		Page 109		rage III
	1	metabolism. And as I mentioned here,	1	are differences, we need to think
	2	the formation of n7 guanine adducts	2	about those differences, but they
			3	don't deny the basic facts of the
	3	has been demonstrated from	3 4	carcinogenicity bioassays. And I
	4	naphthoquinone metabolism.		
	5	Now, let me make a few comments	5	think that that kind of speculation
	6	about the bioassays. The first point,	6	makes it more difficult but doesn't
	7	I think, needs to be emphasized and	7	necessarily illuminate the final
	8	reemphasized, and that is that the	8	answers.
	9	neuroblastomas are rare tumors which	9	So, I would argue that when we
	10	satisfies the definition to an unusual	10	look at the metabolism in a complex
	11	degree in a single experiment, et	11	fashion rather than simply focusing on
	12	cetera. These are rare tumors, and if	12	the stereochemistry of the epoxide
	13	you look at the data, the NTP 2000	13	formation, what we find are
	14	historical controls found zero cancers	14	mechanistic pathways that are entirely
	15	out of 299 males, zero cancers out of	15	believable and reasonable and that we
	16	299 females, and this is not a	16	should consider them quite seriously
	17	particularly small number of controls	17	when we think about making our final
	18	by any stretch of the imagination.	18	determination. Obviously, we have a
	19	And, of course, there is no	19	Ven vellagined structural class of
		evidence that the feed was linked to	20	substances in this case and as I
	20	the tumor. The NIH07, as you note in	21	substances in this case, and as I already said, the mouse solutions obviously
	21		22	not sufficient, but it certainly
	22	my document, the NIH07 need has not	23	provides importance, evidence.
	23	seen these cancers in other species.	23	Finally, In Stanciusion, I think
	24	I think one has to be very careful, and we do this all the time	25	that one needs to look at the
1	25	carefuland we do this all the time	2.5	
Γ				
		Page 110		Page 112
		-	1	-
	1	these daysto suggest that	1	metabolic information from a hazard
	2	these daysto suggest that cytotoxicity and carcinogenicity follow	2	metabolic information from a hazard identification standpoint, and in that
	2 3	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me	2 3	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the
	2 3 4	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies	2 3 4	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the
	2 3 4 5	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those	2 3 4 5	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow
	2 3 4 5 6	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings.	2 3 4 5 6	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic
	2 3 4 5 6 7	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack	2 3 4 5 6 7	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain
	2 3 4 5 6 7 8	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel,	2 3 4 5 6 7 8	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds.
	2 3 4 5 6 7 8 9	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of	2 3 4 5 6 7 8 9	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier?
	2 3 4 5 6 7 8 9 10	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center.	2 3 4 5 6 7 8 9 10	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr.
	2 3 4 5 6 7 8 9 10 11	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect	2 3 4 5 6 7 8 9 10 11	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your
	2 3 4 5 6 7 8 9 10 11 12	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his	2 3 4 5 6 7 8 9 10 11 12	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from
	2 3 4 5 6 7 8 9 10 11	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document	2 3 4 5 6 7 8 9 10 11	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document?
	2 3 4 5 6 7 8 9 10 11 12	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the	2 3 4 5 6 7 8 9 10 11 12 13 14	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are
	2 3 4 5 6 7 8 9 10 11 12 13	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document	2 3 4 5 6 7 8 9 10 11 12 13	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor
	2 3 4 5 6 7 8 9 10 11 12 13 14	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor Penning at the University of
	2 3 4 5 6 7 8 9 10 11 12 13 14 15	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the rat and human in terms of nasal	2 3 4 5 6 7 8 9 10 11 12 13 14 15	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor Penning at the University of Pennsylvania, and I will give you the
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the rat and human in terms of nasal passages, and at the end, he suggests	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor Penning at the University of Pennsylvania, and I will give you the reference, if you would like.
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the rat and human in terms of nasal passages, and at the end, he suggests that more research is necessary in a classic academic context. That is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor Penning at the University of Pennsylvania, and I will give you the reference, if you would like. DR. PORTIER: That would
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the rat and human in terms of nasal passages, and at the end, he suggests that more research is necessary in a classic academic context. That is what we all do, of course.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor Penning at the University of Pennsylvania, and I will give you the reference, if you would like. DR. PORTIER: That would be great, if you could just give us
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the rat and human in terms of nasal passages, and at the end, he suggests that more research is necessary in a classic academic context. That is what we all do, of course. But there is no evidentiary	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor Penning at the University of Pennsylvania, and I will give you the reference, if you would like. DR. PORTIER: That would
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the rat and human in terms of nasal passages, and at the end, he suggests that more research is necessary in a classic academic context. That is what we all do, of course. But there is no evidentiary basis, based on Harkema's document,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor Penning at the University of Pennsylvania, and I will give you the reference, if you would like. DR. PORTIER: That would be great, if you could just give us
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the rat and human in terms of nasal passages, and at the end, he suggests that more research is necessary in a classic academic context. That is what we all do, of course. But there is no evidentiary basis, based on Harkema's document, that would argue persuasively for a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor Penning at the University of Pennsylvania, and I will give you the reference, if you would like. DR. PORTIER: That would be great, if you could just give us the reference afterwards. Thank you. DR. FROINES:
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21	these daysto suggest that cytotoxicity and carcinogenicity follow a common mechanism. It seems to me that the evidence in these studies does not necessarily support those findings. I read with some interest Jack Harkema's report to the panel, comments. Jack Harkema is a member of our air pollution research center. I work with him very closely, I respect him a great deal, and if you read his report very closely, he does document the differences in species between the rat and human in terms of nasal passages, and at the end, he suggests that more research is necessary in a classic academic context. That is what we all do, of course. But there is no evidentiary basis, based on Harkema's document,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	metabolic information from a hazard identification standpoint, and in that regard, the metabolites, that is, the naphthoquinones certainlyand the reactive oxygen species that follow certainly are an important mechanistic pathway that could, in part, explain the carcinogenicity of these compounds. Dr. Portier? DR. PORTIER: Yes, Dr. Froines, just for the record, your figure 2 and figure 3, are those from a published document? DR. FROINES: Those are from a published document by Trevor Penning at the University of Pennsylvania, and I will give you the reference, if you would like. DR. PORTIER: That would be great, if you could just give us the reference afterwards. Thank you.

Quite the opposite. I think that what Jack's work demonstrates is that there

County Court Reporters, Inc. CCP

•

25

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM Registered Protessional Reporters Certified Video Technicians **Drofessional Deporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

25

WASHINGTON, DC LEESBURG, VA Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

comments, questions from the

•

HARRISONBURG. VA

Pages 113 to 116

13538-1 - NIEHS MEETING - 11/19/02

Page 113

1 subcommittee? DR. FROINES: Oh, I 2 should say one other thing. I'm 3 sorry. I've mentioned the catalytic 4 5 behavior, but I did want to mention that lots of times, one doesn't see 6 7 reports of these quinones as much as 8 one might expect, and what we have 9 found in our laboratory is that they are very difficult to analyze in terms 10 11 of the GC/MS, and we've had to develop new methods of analysis using acetic 12 anhydride derivatization in order to 13 adequately quantify the 1,2- and 1,4-14 naphthoquinones. So, I think some of 15 the fact that you haven't seen them as 16 much as one might hope is based on 17 the fact that you simply can't analyze 18 19 for them using traditional methods. 20 DR. SMITH: Yes DR. POPP: Yes I think there is a lot of data on the table 21 22 with this particular compound and a 23 lot of it very interesting and data 24 25 that leads to the need for additional

Page 114

1	data, again, addressed in Jack	
2	Harkema's document. I think that	
3	where this really comes down to for	
4	our purposes today is the question	
5	that Dr. Roberts raised and, I think,	
6	Dr. Froines really answered, and that	
7	is, what criteria should we be looking	
8	at to make the decision today?	
9	And I believe that the issue	
10	comes to whether we have a tumor that	
11	is to an unusual degree in regards to	
12	incident site or type of tumor or age	
13	at onset, as read straight out of the	
14	criteria, and I think it comes down to	
15	even a subset of that, and that is an	
16	unusual degree in terms of tumor type.	
17	There is no doubt that the	
18	neuroblastoma is a very, very unusual	
19	tumor type for the rodent. It is	
20	documented in the material we have.	
21	The table shows us 299 male, 299	
22	female rats, all of which are negative	
23	with the current NIH 2000 diet. The	
24	previous diet, we have background of	
25	over 1000 females, over 1000 males.	

Page 115

and, again, the incidence is zero, and 1 that is consistent with pathologist, 2 3 if you go talk around, who read 4 carcinogenicity studies. That is consistent with, I am sure, everyone's 5 6 experience with this strain of rat and 7 any other strain of rat, as far as I 8 know. In other words, it is a very 9 rare tumor. So, I think when you look at 10 the numbers here where, in one set, we 11 have an incidence of over 25 percent 12 13 of this particular tumor. 14 The next point is that this is very, very clearly a malignant tumor, 15 too. I think, for the non-16 pathologists, the term neuroblastoma 17 may leave one wondering, but just read 18 the cescription in the original NTP report, and the local invasion, in several cases, through the cribriform plate into the brain, there is no doubt that this is a malignant tumor. 20 21 22 23 The elagrosus of malignancy, of course, is supported by Jack Harkema's

Page 116

1	reading. He used a slightly different
2	terminology. I believe he called it
3	neuroepithelioma
4	olfactoryneuroepithelioma carcinoma
5	olfactory, clearing indicating that a
6	number of these are malignant tumors.
7	So, again, I personally think
8	that it comes down to the issue of do
9	we have a malignant tumor to an
10	unusual incidence, and I think the
11	data clearly says we do.
12	DR. SMITH: A quick
13	question of clarification. The table
14	in the document refers to metastases
15	and invasion. Which is it?
16	DR. FROINES: Where are
17	you looking in the document?
18	DR. SMITH: At page .29.
19	I was quite intrigued that the
20	metastases listed 4 out of the 12
21	tumors at the high dose in females,
22	but it is just a minor point of
23	clarification.
24	DR. FROINES: I'm sorry.
25	SPEAKER: In the

County Court Reporters, Inc.

WASHINGTON, DC

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM Desistered Droitessional Deporters Certified Video Technicisna Drofessional Deporting Since 1975

FAX 540.667.6562 www.courtreportingservices.com

HARRISONBURG, VA

STEPHENSON, VA

Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

LEESBURG VA

Pages 117 to 120

13538-1 - NIEHS MEETING - 11/19/02

Page 117

1	description.
2	DR. FROINES: Oh, oh,
3	I'm sorry. Yeah, in essence, it's a
4	matter of terminology. I don't think
5	there is any difference here. I was
6	looking back in the original document,
7	and I believe it stated that there was
8	invasion through the cribriform plate.
9	One could use view that as metastasis.
10	I would personally view it as local
11	invasion, but it makes no difference.
12	Metastasis or invasion is malignancy.
13	DR. SMITH: Thank you.
14	Other comments, questions? Yes?
15	DR. CARPENTER: Could we
16	get back to mine?
17	DR. SMITH: Oh, sure.
18	DR. CARPENTER: One of
19	the real questions that I saw raised
20	in the comments was the fact that the
21	mouse data were, by and arge, not
22	significant, because they aidn't show
23	both sexes, and when I love at that
24	closer, you know, I understand the
25	idea of historical controls, but,

Page 118

	1090 110	I
1	clearly, you have got an increase in	ļ
2 3	adenomas compared to the experimental	
3	controls, and there would appear to be	1
4	an increase in carcinomas compared to	ł
5	the experimental controls, but I don't	
6	remember anything in the	
7	documentmaybe a faulty memorybut	
8	I don't remember anything in the	
9	document where that was discussed	
10	other than to say that it was not	1
11	considered to be significant based on	
12	historical controls, and I kind of	
13	wonder about that. Can we get an	
14	explanation?	
15	DR. PORTIER: Perhaps it	
16	would help to know a little bit about	
17	how a pathologist, if I could just	
18	tell you a little bit about how these	
19	tumors were diagnosed. These are	
20	generallythe difference between an	
21	adenoma and a carcinoma is generally	
22	one of size. It is not one of	
23	fundamental character.	
24	So, the typical background	
25	rates in males for the BCC mouse for	

Page 119

adenomas, at least now, run about 15 1 2 percent for adenomas and 15 percent 3 for carcinomas. We saw zero carcinomas in this particular study. 4 The naphthalene study was done 5 some time ago, and the mouse study was 6 done before the rat study. So, I 7 can't tell you about whether the 8 diagnostic criteria were the same at 9 that time as they are now or the 10 adenoma and carcinoma, but I think it 11 is unusual to see zero carcinomas in a 12 control group in mice. So ... 13 14 DR. CARPENTER: But you saw both male and female? 15 DR. PORTIER: Well, the 16 female generally runs less. They run 17 about half the combined lung tumors 18 than the males. So, they generally run abour 15 percent total combined tumors for the females. So, to see 20 21 no carcinomas in females is less than usual, but to see no carcinomas in 22 23 males, just based on the numbers... I'm sorry. I'm speaking solely

Page 120

1	of the control groups. Did that help?
2	DR. CARPENTER: I guess
3	it goes back to lack of understand of
3 4	this local control and the importance
5	compared to the experimental controls,
6	and you gave me a little bit more
7	information, but the techniques may be
8	different now in terms of
9	interpretation of the pathology which
10	would make the use of historical
11	controls less appropriate in my mind.
12	And my real question is why
13	didn't somebody in this report make a
14	bigger deal out of the fact that you
15	do see what appears to be, although it
16	is listed as a non-significant trend,
17	an increase in adenomas and carcinomas
18	compared to control is the bottom
19	line. It seems to me that that would
20	be an important point of discussion at
21	the very least.
22	DR. POPP: Let me ask a
23	question about the use of controls.
24	My understanding of how the NTP has
25	always used control data is the

County Court Reporters, Inc. ١

TOLL FREE 800.262.8777 CCROCOURTREPORTINGSERVICES.COM

•

Registered Professional Reporters Certified Video Technicians **Drofessional Deporting Since 1975**

Ľ

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

LEESBURG, VA WASHINGTON, DC Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

HARRISONBURG, VA

•

Pages 121 to 124

13538-1 - NIEHS MEETING - 11/19/02

1 2

3

4

5

6

7

8

9

Page 121

	-
1	immediate historical control data. In other words, you would have been using
2	historical control data from the time
3	
4	at which the study was done. So, I
5	don't think whether there has been any
6	drifting criteria or not is really
7	relevant, I don't believe.
8	DR. PORTIER: The
9	studies are generallyobviously,
10	concurrent control is the first line
11	of comparison.
12	DR. POPP: Right.
13	DR. PORTIER: And
14	statistics here are not significant.
15	So, one would then rely on historical
16	control information which, in any
17	case, would argue that there were more
18	carcinomas in historical control
19	animals than appeared here. So, it
20	would argue that it is even less of a
21	concern.
22	DR. SMITH: Can I ask a
23	question on
24	DR. PORTIER: Flust
25	want to answer Dr. Carpenter's
	inentite anienter entre

Page 122

	-	
1	question sort of directly, hopefully.	1
2	Now, looking through the naphthalene	2
3	study in the mouse, that was done in	3
4	1992. The primary tests that were	4
5	used at that time, they used three	5
6	primary statistical tests for	6
7	evaluating, the trend test, the Peters	7
8	life table analysis, and the logistic	5 6 7 8
9	regression prevalence test.	9
10	And if you look at p values	10
11	across those three tests and see that	1'
12	the trend test has a margin of 0.05	12
13	statistical significance; the logistic	1: 1: 1:
14	regression is not at all significant,	
15	0.5; and the lethalitylethal tumor	1
16	analysis is negative, the	10
17	interpretation of the entity at that	1
18	time in looking at that type of	1
19	evaluation for something that had such	
20	changes in survival early on, as this	2
21	particular study did, was a difficult	2
22	decision by the panel in terms of	2
23	making a final review of this, and I	2
24	think that is probably what happened	2
25	here, is in looking at these, because	2

Page 123

there was a survival difference, in looking at these p values, they really didn't know what to call it in terms of their overall evaluation. John, did you... DR. SMITH: I was actually going to ask for the p values. What was the first one you mentioned, the first test of actual p 10 values? DR. PORTIER: The line 11 table test...this is on page A86 in 12 13 your background document looking at mice, alveolar-bronchial adenomas and 14 carcinomas, the logistic...the line 15 table test gives p value of 0.363 with 16 17 a negative trend; the logistic regression test gave a p value of 18 value of 054. All of those are trend tests, and the difference between the logistic regression test and the life table tests as to do with the assumption of whether the 9 20 21 22 23 tumors you are looking at are lethal

Page 124

1	or not lethal, and in the case where
2	you have big survival differences, you
3	get big switches, big switches in the
4	statistical significance, anything in
5	the direction of the finding for
6	statistical significance.
7	This would not happen with
8	current methods used by the NTP, but
9	we don't have those numbers in front
10	of us to be able to tell you what the
11	answer would be based on current
12	statistical methods.
13	DR. SMITH: Of those
14	tests, the ones that are based on
15	incidence, as I understand it, is the
16	Armitage trend andwas that a one-
17	tailed test, p value?
18	DR. PORTIER: In this
19	case, no, that would be a two-tailed
20	test p value. It is a squared two-
21	tailed evaluation.
22	DR. SMITH: Thank you.
23	DR. JAMESON: One point
24	that I neglected to bring out in my
25	presentationI meant to and I

County Court Reporters, Inc. CCR

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM Registered Protessional Reporters Certified Video Technicians **Drofessional Deporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

LEESBURG, VA WASHINGTON, DC Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

HARRISONBURG, VA

Pages 125 to 128

13538-1 - NIEHS MEETING - 11/19/02

Page 127

Page 125

	ruge 120		
1	apologizeis there was a significant	1	there are some also some tests missing
2	decrease in survival of the control	2	here that haven't been done, as far as
3	animals in the male mice in this	3	l can see, such as a bone marrow
4	study. It was attributed to fighting.	4	micronucleus assay. So, we don't have
5	So, that may also contribute to why	5	the complete set of even the
6	you see a zero in the carcinomas in	6	regulatory ones, but there are some
7	the control in this particular group	7	positive ones.
8	study, because there was a significant	8	I think what you have to do
9	decrease in the survival of the	9	with this dataand I'll have to
10	control animals.	10	confess I haven't done itis to look
11	DR. CARPENTER: 1	11	at each study on its merits rather
12	actually make a comment in my document	12	than trying to apply a sort of score
13	here about that, too, and I wonder	13	card as to how many tests are positive
14	about using a control group that	14	and how many negative. So, there are
15	apparently underwent such stress that	15	some positives here, and I think that
16	most of it was eliminated by the end	16	has to be taken into consideration.
17	of the study.	17	DR. SMITH: Dr. Froines?
18	DR. SMITH: Test data	18	DR. FROINES: 1 just
19	exposed.		wanted there emphasize that with the
20	DR. CARPENTER: In this	20	guinene that that there are four Ames
21	case, yes.	21	testsArmes strains that are positive.
22	DR. SMITH: Any other	22	So, it is rather, at least the
23	comments? Dr. Phillips?	23	sort of traditionall agree with
24	DR. PHILLIPS: IN	24	everything Daversaid. I think that
25	could just make a brief comment on the	25	even in an attritional context, there

Page 126

1genotoxicity data. The comment was made that on the weight of evidence, it was overwhelmingly negative. 11are positive results, especially in the p53 which is a modern mutational frequency study that needs to be taken with some seriousness as opposed to the more traditional mutagenicity assays that we tend to list.4think you really can't apply weight of evidence across genotoxicity studies.4the p53 which is a modern mutational frequency study that needs to be taken with some seriousness as opposed to the more traditional mutagenicity assays that we tend to list.6What a genotoxicity study tells flawed in how they do it. That's why any compound has to be considered by a any compound has to be considered by a any compound has to be considered by a 105DR. SMITH: I take it the strain work, it has appeared in publication?10large battery of tests, and there are regulatory tests, and sometimes non-regulatory tests, and sometimes non-regulatory one.10IBR. FROINES: Yes, ITH: Now, on the table, at least, there is some difference of opinion as to how this table, at least, there is some difference of opinion as to how this table, at least, there is some16So, I think, when looking at negative. Mostly, bacterial tests, in time regative, and what that to megative, and what that to megative, and what that to are negative, and what that to are negati	Page 126	Page 128
15non-regulatory one.15difference of opinion as to how this16So, I think, when looking at16chemical should be classified, and I17naphthalene, there obviously are a17think in the final discussion, we18large number of tests which are18ought to try to discover or bring out19negative. Mostly, bacterial tests, in19if there have been any other changes20vitro are negative, and what that20in viewpoints or any points of21probably is telling us is that we21clarification or questions that might22don't have the right system there for22alter the way some of us voteor I	 genotoxicity data. The comment was made that on the weight of evidence, it was overwhelmingly negative. 1 think you really can't apply weight of evidence across genotoxicity studies. What a genotoxicity study tells you isthey are all inherently flawed in how they do it. That's why any compound has to be considered by a large battery of tests, and there are regulatory tests, and sometimes compounds are negative on the 	 are positive results, especially in the p53 which is a modern mutational frequency study that needs to be taken with some seriousness as opposed to the more traditional mutagenicity assays that we tend to list. DR. SMITH: I take it the strain work, it has appeared in publication? DR. FROINES: Yes, it'sI think it represents a very important finding, in fact. DR. SMITH: Now, on the
23 metabolically activating naphthalene at 23 won't be votingsome of us will be	 non-regulatory tests, and sometimes compounds are negative on the regulatory tests, but the come up on a non-regulatory one. So, I think, when looking at naphthalene, there obviously are a large number of tests which are negative. Mostly, bacterial tests, in vitro are negative, and what that probably is telling us is that we don't have the right system there for 	12important finding, in fact.13DR. SMITH: Now, on the14table, at least, there is some15difference of opinion as to how this16chemical should be classified, and I17think in the final discussion, we18ought to try to discover or bring out19if there have been any other changes20in viewpoints or any points of21clarification or questions that might
251000 Series and24voting.24all.24voting.25There are some positives, and25DR. ROBERTS: Yes, and	24 all.	24 voting.

County Court Reporters, Inc. Qr '(

TOLL FREE 800.262.8777 CCR@COURTREPORTINGSERVICES.COM

•

Registered Protessional Reporters Certified Video Technicians Drofemiousl Deporting dince 1975

٠

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

LEESBURG, VA WASHINGTON, DC Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22856

HARRISONBURG, VA

٠

Pages 129 to 132

Page 129

	5
1	as I mentioned in my comments, the
2	issue that was sort of outstanding for
3	me was the and I thought was a
4	pivotal issue on this one was the
5	issue of the criteria with regard to
6	the unusualness of the tumor response
7	in the male rats, and I thought Dr.
8	Popp gave me a very good response that
9	I found convincing. So, I would think
10	that thatagree with him that
11	that's, in my mind, the most
12	compelling basis to list this
13	compound.
14	DR. SMITH: Any other
15	points? Discussions?
16	(No response.)
17	DR. SMITH: Can somebody
18	movemake a motion to
19	DR. CARPENTER: I move
20	that naphthalene bethat we vote to
21	consider naphthalene or list
22	naphthalene as reasonably anticipated
23	to be carcinogenic in humans.
24	
25	DR. SMITH: Seconded by
	•

Page 130

1	Frumpkin. Ready to vote? I am a
2	novice. It's my one chemical
3	discussion. You will be replaced.
2 3 4	DR. FROINES:
5	Absolutely.
6	DR. SMITH: Any
7	discussion?
8	(No response.)
9	DR. SMITH: Calling the
10	vote. Those in favor?
11	(Show of hands.)
12	DR. SMITH: It's a
13	unanimous vote. Thank you.
14	I suggest that we stop for
15	lunch. What time do we meet back?
16	DR. WOLFF: 1:15.
17	DR. SMITH: It is 12:15,
18	so, 1:15.
19	SPEAKER: is lunch
20	served, or are we on our own?
21	DR. WOLFF: You are on
22	your own. Actually, the hotel has a
23	restaurant, and if you just walk out
24	the front door, you'll see a number of
25	eateries on the street and adjacent to

County Court Reporters, Inc.

•

TOLL FREE 800.262.8777 CCRCCOURTREPORTINGSERVICES.COM

.

Registered Professional Reporters Certified Video Technicians **Professional Reporting Since 1975**

FAX 540.667.6562 WWW.COURTREPORTINGSERVICES.COM

STEPHENSON, VA

LEESBURG, VA WASHINGTON, DC Corporate Offices: 1160 Jordan Springs Road, STEPHENSON, VA 22656

HARRISONBURG, VA

•

Attachment **B**

Correspondence

COURTNEY M. PRICE VICE PRESIDENT CHEMSTAR



November 27, 2002

Via FedEx and E-Mail

Kenneth Olden, Ph.D. Director, National Toxicology Program MD B2-01 P.O. Box 12233 Research Triangle Park, NC 27709-2233

Re: National Toxicology Program (NTP) Board of Scientific Counselors (BSC) Report on Carcinogen (RoC) Subcommittee Review of Proposed Naphthalene Listing at the November 19, 2002 Meeting

Dear Dr. Olden:

I write on behalf of the Naphthalene Panel (Panel) of the American Chemistry Council to protest the grave procedural improprieties that occurred during the BSC RoC Subcommittee's November 19, 2002, meeting to review naphthalene's listing as a carcinogen. To rectify these serious breaches of due process – which are detailed below – we request that you nullify the Subcommittee's vote on naphthalene and take other corrective measures. The nomination to list naphthalene should be returned to the Subcommittee to allow panel members and other interested parties to review and comment on new information – disclosed for the first time at the November 19 meeting – and the naphthalene listing should be taken up again at the next BSC RoC Subcommittee meeting. If, after reading why we propose these steps, you decline to provide our requested relief, we would ask for an immediate meeting with you to discuss this matter before you make a final decision to recommend listing naphthalene to the Secretary of the Department of Health and Human Services.

The Panel worked diligently and in good faith to supply pertinent information in a timely fashion to the NTP to prepare for the November 2002 Subcommittee meeting. These efforts were made in the spirit of transparency, consistent with the NTP's commitment to conduct NTP proceedings with openness and due process. We were surprised when the Subcommittee Chairman, Dr. John R. Froines removed himself from the role of Chairman during consideration of naphthalene so that he could express his views on the naphthalene nomination and then vote on its proposed listing. We do not dispute that it was appropriate for Professor Froines temporarily to cede the role of Chairman to permit participation in scientific

Responsible Care*

deliberations. Nor do we object to a knowledgeable scientist offering a dispassionate, unbiased opinion, based on scientific knowledge, on the proposed listing of naphthalene. The views expressed, however, were neither dispassionate nor unbiased, but constituted new information offered in a context devoid of due process and transparency. Indeed, the timing of Dr. Froines' presentation precluded any opportunity for others interested in and at least equally knowledgeable about these matters to address his statements on their merits. Dr. Froines' actions were plainly not those of a member of an "independent peer review group" consistent with the charge given to Subcommittee reviewers, and strongly suggest egregious bias.

Rather than working as an active participant of the Subcommittee and contributing to its discussions, Professor Froines pursued his own agenda and caught meeting participants completely unprepared by presenting new information that had not previously been shared with the Subcommittee, nor made a part of the public record. After NTP staff made their oral presentation of the basis of the nomination of naphthalene, and after presentation of interested stakeholder comments, the Subcommittee recessed briefly during which time Dr. Froines distributed written materials to Subcommittee members. Copies of these materials were not made available to the public before, during or, to our knowledge, after the meeting. During his presentation, Dr. Froines referenced a metabolic pathways diagram and was asked by a Subcommittee member to show the diagram to the Subcommittee. He was unable to do so. Dr. Froines discussed research results and was asked by NTP staff if the research had been published. He reported that it had, but was unable to provide any references to the published work.

During his remarks, Dr. Froines argued that naphthalene should be listed for at least three reasons. Scientific documentation of none of these points was part of the record before the Subcommittee.

First, Dr. Froines argued that naphthalene belongs to the class of chemicals known as polycyclic aromatic hydrocarbons (PAHs) which, he stated, are "known carcinogens." It is well known that the scientific community lacks consensus on the categorization of naphthalene as a PAH, and that it is inaccurate and scientifically indefensible to state categorically that all PAHs are "known carcinogens." The International Agency for Research on Cancer (IARC) has expressly addressed this issue. Volume 32 of the *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans* discusses the carcinogenicity data on 42 PAH compounds. Following the Preamble, IARC scientists state that "only condensed aromatic hydrocarbons and aza arenes with three or more rings are considered" in their review of PAHs and heterocyclics that have been tested for carcinogenicity¹ and that occur in the environment. More importantly, it is well known that the classification of PAHs is disputed. Although it is true that 15 or so PAHs are considered as known experimental or animal carcinogens, and several are considered to be human carcinogens, many others are not

¹ Although the NTP bioassays on naphthalene were not completed until after publication of IARC volume 32 in 1983, at least three independent cancer bioassays and one cell transformation assay on naphthalene were published at the time of the IARC review. Included in that Monograph are reviews on a number of PAH compounds with less experimental data available than that for naphthalene in 1983.

considered carcinogenic at all. Anthracene, fluoranthene, 1-methylchrysene, and pyrene are examples of PAHs that have been evaluated for carcinogenicity and are considered not carcinogenic by IARC, by NTP, and by the U.S. Environmental Protection Agency (EPA).² There is no information, however, regarding categorization of naphthalene as a PAH in any of the nomination or background materials presented by NTP in support of the nomination of naphthalene to the RoC.

A second reason given by Dr. Froines for listing naphthalene is that it is a component of "urban air pollution." While undoubtedly the case, as naphthalene is a component of gasoline as well as other incompletely combusted organic sources such as cigarette smoke and burning wood, occurrence in "smog" alone is not a reason for listing naphthalene as a carcinogen. The Subcommittee was not provided nor given the opportunity to consider any data regarding evidence of carcinogenicity related to exposure to naphthalene in urban air pollution as it may relate to human cancer incidences.

A third reason offered by Dr. Froines to list naphthalene, and equally of concern, was his summary dismissal of published research on the metabolism of naphthalene and certain of its primary metabolites, calling this research "speculative." This "speculative" metabolism data are those presented by NTP in its assessment of naphthalene as well as by other governmental science agencies such as IARC, the U.S. Agency for Toxic Substances and Disease Registry (ATSDR), and the United Kingdom's Health and Safety Executive. Promoted in its place was research conducted in Dr. Froines' laboratory and said to have been published. The alternative metabolic pathway presented contains mutagenic metabolites, and is itself considered speculative, at best, by other academic researchers in the field. Although Dr. Froines admitted that standard genotoxicity assays for naphthalene were negative, he stated that certain specialized genetic toxicology studies (for which no data were presented) would demonstrate positive responses when metabolism is considered.

Metabolism is considered in the standard genetic toxicology assay. Metabolic activation is included in most *in vitro* assays with both bacterial and mammalian cells. Further, *in vivo* studies are considered more predictive than *in vitro* studies because direct metabolism occurs in the animal model. As presented in comments submitted to NTP by the American Chemistry Council Naphthalene Panel³, nearly 40 genotoxicity studies have been published on naphthalene. The weight-of-evidence plainly demonstrates that naphthalene is not genotoxic. This has been recognized by NTP and other United States and international scientific agencies. Considering the role of metabolism in this large volume of genetic toxicology studies, it would be expected that a metabolite as significant as that described by Dr. Froines, in combination with the high test concentrations or doses used, would have led to significant positive results in a large number of the genetic toxicology assays of naphthalene. Such is not the case, however.

² See EPA's Integrated Risk Information System (IRIS) documents for these chemicals, available online at http://www.epa.gov/iris/.

³ Public comments submitted to NTP regarding the proposed naphthalene listing are posted on NTP's web site at http://ntp-server.niehs.nih.gov/newhomeroc/rocllnaphthalene.html.

We are deeply concerned that the new information presented to the Subcommittee during its deliberations, including categorically incorrect statements regarding PAHs and naphthalene, unsubstantiated assertions regarding naphthalene's genotoxicity, and remarks concerning naphthalene's alleged role in urban air pollution inappropriately influenced the Subcommittee's decision to vote to list naphthalene. We are especially troubled that none of the information on which Dr. Froines relied was the subject of prior notice, public comment, or deliberation by the RG1 and RG2 Committees. None of the new information is included in the naphthalene background document. Most importantly, none of the new information was externally peer reviewed, which is precisely what the Subcommittee is charged with doing, because one of the Subcommittee members served the dual role of "independent peer reviewer" and sole source of the information. Subcommittee members cannot have it both ways and we request that you, as Director of the NTP, not countenance these improprieties.

The Panel respectfully submits that, if the new data and interpretations of these data introduced at the Subcommittee meeting are of integral relevance to the evaluation of naphthalene's carcinogenicity, there is every reason to have made the data and the arguments available to Subcommittee members and to the public in a timely fashion, and to have allowed appropriate consideration of these data before decisions were made. NTP has gone to great lengths to make the RoC listing process more transparent, and has succeeded, for example, in making relevant documents highly accessible through effective use of the NTP website. Dr. Froines did not make these materials available beforehand. A recommendation to list naphthalene based on information not in the public record has compromised the listing process and the transparency of that process with respect to naphthalene.

In light of the foregoing, we request that you nullify the Subcommittee's vote on naphthalene, refer the naphthalene nomination back to the Subcommittee, request that Dr. Froines submit to the record all pertinent information that he wishes to be considered for listing purposes, allow interested parties an opportunity to review and comment upon the new information, and re-consider naphthalene's nomination at the next RoC Subcommittee meeting. This relief must be provided to fulfill the letter and spirit of NTP's RoC listing procedures. If you decline to provide this relief, we ask that you advise us of your decision before you forward a recommendation to list naphthalene to the Secretary to enable us to meet with you to discuss this matter.

The Panel believes strongly that NTP's scientific credibility has been compromised by the events of the November 19, 2002, RoC Subcommittee meeting and that it is essential you provide the relief requested to restore the credibility that has been lost as a consequence of these events. The message that NTP would communicate in failing to provide the relief requested is a chilling one, and could significantly harm the distinguished reputation you and others have worked hard to promote. We are confident that you will work quickly to renew NTP's commitment to scientific rigor, due process, and openness, and look forward to your response.

If you require additional information, please contact Dr. Anne P. LeHuray at (703) 741-5630 or <u>anne_lehuray@americanchemistry.com</u>.

Sincerely,

Courtney M. Price, Vice President, CHEMSTAR

cc: Dr. Christopher Portier, NTP

Dr. C.W. Jameson, NTP

Dr. Henry Falk, Agency for Toxic Substances & Disease Registry (ATSDR)

Mr. Thomas Moore, Acting, U.S. Consumer Product Safety Commission (CPSC)

Ms. Christine Whitman, U.S. Environmental Protection Agency (USEPA)

Dr. Mark McClellan, Commissioner, Food & Drug Administration (FDA)

Dr. Richard Jackson, National Center for Environmental Health (NCEH)

Dr. Andrew von Eschenbach, National Cancer Institute (NCI)

Dr. Ruth Kirschstein, Acting, National Institutes of Health (NIH)

Dr. Kathleen Rest, Acting, National Institute for Occupational Safety & Health (NIOSH)

Dr. John L. Henshaw, Occupational Safety & Health Administration (OSHA)

JAN-29-2003 14:48

ACC CHEMSTAR



NATIONAL TOXICOLOGY PROGRAM

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES 111 T.W. ALEXANDER DRIVE P.O. BOX 12233 RESEARCH TRIANGLE PARK, NC 27709-2233 919-541-0530; Fex 919-541-0295

January 27, 2003

Ms. Courtney M. Price Vice President, CHEMSTAR American Chemistry Council 1300 Wilson Boulevard Arlington, Virginia 22209

Dear Ms. Price:

Thank you for your letter dated November 27, 2002, on behalf of the Naphthalene Panel of the American Chemistry Council (ACC) concerning the National Toxicology Program's (NTP) review of naphthalene for possible listing in the Report on Carcinogens (RoC). Your letter raises issues regarding the naphthalene nomination review at the November 19-20, 2002, meeting of the NTP Board of Scientific Counselors RoC Subcommittee. Rather than addressing each point you raise, I offer the following comments. First, I would point out that members of this NTP advisory group are encouraged to bring any published information beyond that provided in the background documents before the Subcommittee for consideration if the member feels it is relevant to the discussion of a nomination. I would also note that public and subcommittee member comments, both written and oral, sometimes raise new issues or provide the Subcommittee and the public before the end of the meeting if a copy of the article is available to us. This was the case for the naphthalene review. A list of the articles provided is enclosed for your information.

I believe that the procedures currently in place provide a full and fair consideration of the nominations for the RoC, and allow one to determine if sufficient information is available to base judgments of whether or not a nomination should be included in the RoC as a *known* or *reasonably anticipated* human cancer hazard. I am sorry that I cannot meet with you concerning the naphthalene nomination, as it is my practice not to meet with individual stakeholders concerning a nomination to the RoC. Let me assure you that any recommendation we will be making to the Secretary for listing substances in the Eleventh Edition of the RoC will be based on sound scientific judgments which were reached following a detailed and complete review of all available information and comments.

ACC CHEMSTAR

Page 2 - Ms. Courtney M. Price

I appreciate your input and will see to it that your comments are included on the NTP RoC website with the other public comments received for naphthalene. For your information, the NTP is in the process of preparing a <u>Federal Register</u> notice containing the recommendations from all three scientific reviews and soliciting final public comment for the 11th RoC nominations that completed review in 2002. We encourage you to submit comments in response to that notice.

Thank you for your interest in the NTP's Report on Carcinogens.

Sincerely yours,

Signature

Kenneth Olden, Ph.D. Director

Enclosure

.

Publications Provided by Dr. John Froines

- Flowers-Geary L, Bleczinski W, Harvey RG, Penning TM. Cytotoxicity and mutagenicity of polycyclic aromatic hydrocarbon o-quinones produced by dihydrodiol dehydrogenase. Chemico-Biological Interactions 99:55-72 (1996).
- McCoull KD, rindgen D, Blair IA, Penning TM. Synthesis and characterization of polycyclic aromatic hydrocarbon o-quinone depurinating N7-guanine adducts. Chemical Research in Toxicology 12:237-246 (1999).
- Penning TM, Burczynski ME, H C-F, McCoull KD, Palackal NP, Tsuruda LS. Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones. Chemical Research in Toxicology 12(1):1-15 (1999). [This articles contains the 2 figures: Scheme 2 and Figure 3]
- Yu D, Berlin JA, Penning TM, Field J. Reactive oxygen species generated by PAH oquinones cause change-in-function mutations in p53. Chemical Research in Toxicology 15:832-842 (2002).

COURTNEY M. PRICE VICE PRESIDENT CHEMSTAR



March 3, 2003

Via FedEx and E-Mail

Kenneth Olden, Ph.D. Director National Institute of Environmental Health Sciences National Toxicology Program P.O. Box 12233 Research Triangle Park, NC 27709-2233

Re: National Toxicology Program (NTP) Board of Scientific Counselors (BSC) Report on Carcinogens (RoC) Pertinent to Naphthalene

Dear Dr. Olden:

Thank you for your letter dated January 27, 2003, sent in response to the Naphthalene Panel (the Panel) of the American Chemistry Council's November 27, 2002, letter. We appreciate your reaffirmation of the NTP's commitment to base *RoC* listing recommendations on "sound scientific judgments" that are the product of "a detailed and complete review of all available information and comments." It is precisely because at this point the naphthalene listing process cannot yield sound scientific judgments consistent with NTP's own procedural requirements or applicable legal mandates that we write. The Panel wishes to ensure that you are fully aware of the significant breaches in this process that have occurred with respect to consideration of naphthalene during the listing process. Because of these improprieties, discussed in detail below, we request that NTP immediately withdraw the *RoC* Background Document for Naphthalene and suspend the comment period on the NTP's Call for Public Comment published on January 22, 2003,¹ as it relates to naphthalene until the Background Document has been revised to reflect fully and accurately "all available information and comments." Acceding to this request is the only course available to NTP that does not compromise its commitment to transparency and due process.

The Panel believes strongly, for all the reasons carefully set forth in our November letter, that the events that transpired on November 19, 2002, at the *RoC* Subcommittee meeting with respect to naphthalene were serious transgressions of due process.² An unexpected technical presentation on naphthalene was delivered to the Subcommittee that

For your convenience, we append a copy of our letter and your response to it.

Responsible Care®

1

2

1300 Wilson Boulevard, Arlington, VA 22209 • Tel 703-741-5600 • Fax 703-741-6091 • http://www.americanchemistry.com

⁶⁸ Fed. Reg. 3033 (Jan. 22, 2003).

included new information that had neither been shared prior to the meeting with the Subcommittee, nor made a part of the public record. This objectionable and inappropriate approach has continued to this day, with the apparent approval of NTP, as *none* of the materials presented -- not the document prepared and distributed to Subcommittee members, not the four technical references provided to NTP after the meeting, not a single word of that presenter's extensive oral remarks -- are yet part of the public record. None of this information was available for public comment before the Subcommittee meeting, after it, or as we write. Indeed, members of the public who were not physically present at the Subcommittee meeting are not even aware that a substantial part of the basis for the Subcommittee's decision is not part of the public record.

This transgression alone is sufficiently egregious to warrant the relief the Panel seeks. In addition, however, the inappropriate behavior that occurred at the Subcommittee meeting is entirely consistent with a course of conduct that is outcome determinative and gives the appearance of bias. More glaring than this transgression is the fact that the Background Document on Naphthalene remains in its original form, its contents unchanged from its August 26, 2002, cover date. The RG1 findings are not reflected in the Background Document, despite the passage of eight months since the RG1's review on June 10, 2002. Similarly, the RG2 findings are not reflected in the Background Document, since the RG2's review date of October 2, 2002. Finally, public comments on the Background Document, such as those submitted by the Panel on October 2, 2002, apparently have not been considered.

None of the newly introduced materials presented and discussed by Subcommittee members at the RoC Subcommittee meeting are reflected in the Background Document. This particular omission is made all the more conspicuous given that the vote on naphthalene's listing was twice split down the middle after two motions at the close of the RG2 Committee review. Indeed, RG2 Committee members were so divided, the Chairman took the unusual step of abstaining from casting a tie-breaking vote and no recommendation was forwarded by the Committee to you for your consideration. The oral representations about the relevance of unreviewed materials made at the RoC Subcommittee meeting were apparently very persuasive as the motion to list naphthalene was "passed by unanimous vote (9/0)."³ Unless the Background Document is withdrawn and rewritten, however, only those who actually attended the Subcommittee meeting will ever know what the Subcommittee found so persuasive. This eclipsing of transparency falls far short of the standard you describe in your letter as one requiring the "detailed and complete review of all available information and comments." Given the Naphthalene Background Document's state of arrested development, and the absence anywhere, including the recent Federal Register notice and the NTP website, of a clear statement of the Subcommittee's deliberative process for voting as it did, NTP's solicitation of "final" public comments on the naphthalene listing is, at a minimum, a meaningless exercise as there is no new information on which to comment. In fact, without granting the relief we seek, NTP's continued solicitation of "final" public comments will only serve to mislead further the public as

³ 68 Fed. Reg. at 3035.

well as the agencies that participate in and rely upon NTP, contributing to a situation much worse than meaningless.

These serious lapses cannot be harmonized with NTP's often stated and very public commitment to transparency, openness, and due process. NTP stated, for example, at the end of the preparation of the 9^{th} RoC:

The NTP is committed to maintaining an open and transparent process for preparation of the RoC that is unencumbered by special interests; includes high quality and open scientific review of substances nominated for listing/delisting; uses the best, publicly available, peer reviewed science; and allows for stakeholder input at multiple levels.... The NTP greatly appreciates the input from all parties and will move forward in implementing some changes immediately while considering other recommendations for possible implementation in the future. In making these changes to the RoC's preparation and review, the NTP is committed to providing the resources needed to ensure their successful implementation.⁴

Similarly, in NTP's responses to previous comments on deficiences in the listing process, NTP wrote:

In reply to the suggestion that the NTP respond to individual comments, the NTP will continue to revise the background documents during the deliberations by Review Groups 1 and 2 (RG1 and RG2, respectively). Following completion of RG2's review, the background documents are considered the document of record and will not be changed in response to any subsequent stakeholder input except to correct errors [italics added for emphasis]. The NTP will make public comments received on all nominations available on its world-wide-website. All comments received by published deadlines will continue to be made available to the BSC *RoC* Subcommittee for its use in the review of nominations. All comments received will also be provided to the NTP Executive Committee and the NTP Director. A summary of stakeholder opinion for each nomination will also continue to be provided to the Secretary.

In response to the concerns expressed about unevenness in the quality of the background documents, the NTP will expand the use

⁴ NTP, "Response to Public Comments and Discussion on the Preparation and Review of the *Report on Carcinogens*" (last revised Oct. 30, 2001), available at http://ntp-server.niehs.nih.gov/NewHomeRoC/ResponsePub.html.

of external, compound-specific experts in their preparation. In addition, these experts will now be invited, as needed, to participate in the BSC *RoC* Subcommittee's meetings and discussions as well. Such situations would include instances where the experts contribute significantly to preparation of the background document or where the scientific issues for the nomination are unusually complex and/or controversial. The NTP believes that this addition of compound-specific expertise will strengthen the BSC *RoC* Subcommittee's review of the nominations.⁵

These safeguards are fair and appropriate, and reflect the high standards NTP has set for itself. They do not, however, reflect the process that has been used for naphthalene's nomination. The Background Document for Naphthalene is in no sense the "document of record," as it documents nothing of the record since last August. Nonetheless, this is the document on which NTP is seeking "final" public comment. The *RoC* Listing Subcommittee meeting last November similarly was characterized by highly unusal, and in our view, impermissible departures from past practices, including the Chairman's self-removal from his role during the consideration of naphthlene so that he could express unsupported, unreviewed comments on naphthalene's nomination and then vote on its proposed listing. In essence, he was acting as a stakeholder. None of this presentation is part of the record, despite the availability of the transcript of the Subcommittee meeting and, presumably, the document distributed to Subcommittee members, but not to the public at the time of the meeting or since.

Other anomolies have occurred in the listing process. For example, the time between the RG2 deliberations (October 2, 2002), the due date for comments (November 4, 2002), and the scheduling of the Subcommittee meeting (November 19-20, 2002) was unually compressed. Typically, more time is allowed to prepare and submit comments. This compressed timeframe is certainly not reflective of the "early input from stakeholders" anticipated in NTP's earlier commitment to ensure "issues critical to evaluating the listing/delisting are addressed during development of the background documents and are considered throughout the review process." In short, the entire listing process for naphthalene has been compromised. As Director of the NTP, and guardian and champion of its commitment to transparency, we urge that you ensure due process is observed. These breaches must be remedied if NTP is to make good on its commitment to transparency and sound science.

To remedy these breaches, the Panel requests that NTP immediately announce in the *Federal Register* its decision to withdraw and rewrite the *RoC* Listing Background Document for Naphthalene and to suspend the public comment period seeking "final" comments on the naphthalene listing. Once the Background Document has been rewritten, and all available and relevant materials essential to naphthalene's listing have been made available to the public, NTP should restart the comment period and seek public comment for an additional 60-day period.

⁵ *Id*.

The Panel continues to believe that the vote taken with regard to naphthalene at the November, 2002 Subcommittee meeting should be nullified and, after all relevant information has been submitted for review, naphthalene should be reconsidered at the next Subcommittee meeting. Failure to do as requested would violate NTP's own operating requirements and expose NTP to allegations of non-compliance with the principles of due process and Office of Management and Budget, Department of Health and Human Services, and National Institutes of Health guidelines for ensuring data quality.⁶

The Panel strongly urges you to remedy these breaches to avert the need for the Panel to pursue other avenues of recourse. As comments on the January 22, 2003 *Federal* Register Notice are due by March 24, we request that you respond by March 14. If the relief requested is not granted, and as you are unable to meet with us, we plan to seek a meeting with Secretary Thompson to discuss this matter.

The Panel looks forward to hearing from your office promptly. If you require additional information, please call or e-mail Dr. Anne P. LeHuray at (703) 741-5630 or anne_lehuray@americanchemistry.com.

Sincerely yours,

<Signed>

Courtney M. Price Vice President, CHEMSTAR

Attachments

6

cc: Dr. Christopher Portier, NTP
 Dr. C.W. Jameson, NTP
 Mr. Tommy Thompson, Department of Health and Human Services (HHS)
 Dr. Dr Elias A. Zerhouni, Director, National Institutes of Health (NIH)

The HHS Information Quality Guidelines are available at http://www.hhs.gov/infoquality/.

DEPARTMENT OF HEALTH & HUMAN SERVICES



703 741 6091 P.01

Public Heelth Service

National Toxicology Program P.O. Box 12233 Research Triangle Park, NC 27709

March 11, 2003

Ms. Courtney M. Price Vice President, CHEMSTAR American Chemistry Council 1300 Wilson Boulevard Arlington, Virginia 22209

Dear Ms. Price:

Thank you for your letter dated March 3, 2003, regarding your concerns about naphthalene. In your letter, you request that the NTP withdraw and rewrite the Report on Carcinogens (RoC) Listing Background Document for Naphthalene ("the Naphthalene Document"), extend the public comment period, nullify the vote on naphthalene by the NTP Board of Scientific Counselors RoC Subcommittee ("the RoC Subcommittee") at its review on November 19, 2002, and bring naphthalene back to the RoC Subcommittee at its next meeting. I cannot agree to any of these requests. The first two requests are discussed below and the remaining requests have been dealt with in my previous response dated January 27, 2003, and will not be addressed again in this correspondence.

The Naphthalene Document is the document of record for all three scientific reviews and will remain the document of record. According to our process, we include all available public comments with the background document and do not alter the background document throughout the review period unless serious errors are detected in it. This assures that our three scientific review committees are basing their decisions on the same basic material augmented by the additional public comments obtained during the review process. I believe that this process is both open and fair, clear to all interested parties, and maintains the scientific rigor necessary for decisions regarding the review of agents for inclusion in the RoC.

My staff informs me that none of the initial two scientific review committees found serious flaws in the Naphthalene Document that would require it being rewritten. Also, I understand that the Naphthalene Document, the recommendations from Review Group 1 (RG1) and Review Group 2 (RG2), and all public comments received to date are posted on the NTP web site. In addition, I am told that the RoC Subcommittee publicly noted your written concerns regarding the exposure information for naphthalene and concluded that there was sufficient exposure to warrant review of this agent for inclusion in the RoC. I also understand that you refer to other sources of exposure information on naphthalene in your comments and we would be happy to receive that information from you.

Page 2 – Ms. Courtney M. Price

I do not agree with your assessment that a written copy of the verbal presentations from the RoC Subcommittee's review must be available to the record prior to the onset of a final comment period. Historically, the NTP has never published the meeting transcript, but it is available upon request. The minutes from the RoC Subcommittee meeting on November 19, 2002, are not yet available on our web site, but these minutes serve more to guide the reader on the progress of the meeting than on the detailed substantive arguments of the presenters and the RoC Subcommittee. The NTP does recognize the importance of informing the public about differences in opinions within each RoC scientific review group with regard to recommended actions for individual nominations; therefore, we publish the reason(s) for any negative votes or abstentions in the Federal <u>Register</u>. The Federal Register notice published January 22, 2003, (Vol. 68, No. 14, Pages 3033 - 3036) containing the recommendations and votes from the three scientific review groups for the set of nominations that includes naphthalene, also contains this explanatory information for any dissenting votes or abstentions. Hence, I see no reason to extend the public comment period due to a lack of a summary from this public meeting.

As you are aware, public comments received in response to this notice will be posted on the RoC web site along with the other comments received to date. I would encourage you to submit comments in response to the January 22nd Federal Register notice. For your information, in the past my staff has included comments received after published deadlines in their briefing to me prior to my developing a recommendation on RoC nominations for the Secretary.

I am sorry that I cannot meet with you concerning this matter, as it is my policy not to meet with individual stakeholders concerning a nomination to the RoC. Please be assured that I have not yet made a decision on the NTP recommendation for any of the nominations being considered for listing in the 11th RoC; and before doing so, I will carefully review the minutes from the review groups' meetings, their recommendations, and all public comments.

I appreciate your providing me input about your concerns.

Sincerely yours,

ΛΛ gnature

Kenneth Olden, Ph.D. Director